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 Depression is highly prevalent among people living with HIV in Malawi and elsewhere 
in sub-Saharan Africa (SSA). Beyond the morbidity produced by depression in its own right, 
depression is also an important barrier to early and consistent HIV care engagement and long-
term viral suppression. Depression treatment has been linked to improved antiretroviral therapy 
(ART) adherence in observational studies, although evidence from interventions is mixed. To 
address the burden of depression among people living with HIV, the Malawi Ministry of Health 
implemented a pilot program that integrates depression screening and treatment into public HIV 
care at two clinics in Lilongwe, Malawi.   
Using abstracted clinical data from patients enrolled in the program evaluation as well as 
in-depth interviews with patients and health care facility staff, this dissertation aims to 1) 
estimate the association between baseline depression and retention in HIV care and viral 
suppression; 2) evaluate the impact of depression treatment on retention in HIV care, viral 
suppression, and depression remission; and 3) explain the success or failure of the program 
implementation using a mixed-methods approach that focuses on fidelity, acceptability and 
sustainability. 
 Among the 1091 participants screened for depression prior to the launch of the treatment 
program included in Aim 1, the prevalence of depression was 27%. Those with depression had 
similar HIV care outcomes at 6 months to those without depression.  
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 Among the participants with elevated depressive symptoms at ART initiation included in 
Aim 2, program exposure did not demonstrably affect most HIV or mental health outcomes, 
though the probability of currently being on ART at 6 months was significantly lower among the 
intervention group than the control group [RR 0.6(95%CI: 0.4-0.9)].  
 The mixed-methods process evaluation presented in Aim 3 found that fidelity to the 
program protocol was poor and the program was not delivered as intended. While 
antidepressants and problem-solving therapy appeared to be acceptable treatment options for 
patients, clinic staff and leadership found delivering this treatment challenging in light of 
constrained human resources and infrastructure. The program was ultimately not sustained. As 
designed and without substantial support to supervise the implementation of the program, 
continue to build and maintain the capacity of providers, integrate the program into the electronic 
medical records system and ensure the availability of counselors, it does not appear feasible to 
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CHAPTER I: SPECIFIC AIMS 
 
Depression is highly prevalent among people living with HIV in Malawi and elsewhere 
in sub-Saharan Africa (SSA). Depression affects 18-30% of patients receiving HIV care in 
Africa.1 Beyond the morbidity produced by depression in its own right, depression is also an 
important barrier to another critical need for those living with HIV – early and consistent HIV 
care engagement and long-term viral suppression.1-6 Depression treatment has been linked to 
improved antiretroviral therapy (ART) adherence in observational studies7-9, although evidence 
from interventions is mixed.10-15 Further evidence is needed about the association between 
depression and retention in care and the impact of depression treatment on mental health and 
HIV care outcomes in Malawi and the sub-Saharan region.  
The SOAR-Mental Health (SOAR-MH) project provided a unique real-world opportunity 
to address this knowledge gap. As part of this project, the Malawi Ministry of Health piloted a 
program that integrates depression screening and treatment into real-world HIV care at two 
public clinics in Lilongwe, Malawi.16  HIV care providers with no prior mental health training 
were trained in depression assessment, diagnosis, and treatment. All patients completed 
depression screening at ART initiation. Providers treated depressed patients with antidepressants 
or referred patients to lay health workers trained to offer problem-solving therapy. All patients 
were followed longitudinally to capture both mental health and HIV outcomes. The program was 
implemented in two phases; a screening-only “control” phase and an active “intervention” phase 
to permit evaluation of program impact. Data from this project provide an outstanding 
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opportunity both to: 1) assess the relationship of depression with HIV outcomes; 2) examine the 
impact of a depression treatment program on those same outcomes; and 3) evaluate the 
implementation of this depression treatment program in the context of real-world HIV services in 
a low-income country in SSA.   
The main objectives of this dissertation are to evaluate the impact of the SOAR-MH 
depression treatment program on HIV care outcomes and depressive symptoms six months after 
ART initiation and to explain the implementation of the program. This dissertation should 
provide urgently needed and critical insight into depression management and HIV care 
engagement in Malawi. The aims of this dissertation are:   
AIM 1: Estimate the association between depressive symptoms at ART initiation 
and HIV care retention and HIV RNA suppression at six months among patients newly 
initiating ART. We used clinical appointment and HIV RNA data collected from 852 patients 
without and 291 patients with elevated depressive symptoms who initiated care during the 
screening-only phase of the SOAR-MH project and examined potential modification by gender. 
We hypothesized that patients with elevated depressive symptoms at ART initiation would be 
less likely to be retained in care and less likely to be virally suppressed six months after ART 
initiation compared to patients without such symptoms.  
AIM 2: Estimate the impact of the depression treatment program on 1) HIV care 
retention, 2) HIV RNA suppression, and 3) depression remission at six months among 
patients with depressive symptoms newly initiating ART. Using an intent-to-treat analysis 
approach, we compared 291 patients with elevated depressive symptoms during the screening-
only phase of the SOAR-MH project to 212 patients with such symptoms during the project’s 
treatment program phase and examined potential modification by gender. We hypothesized that 
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patients during the treatment program phase would be more likely to 1) be retained in HIV care, 
2) be virally suppressed, and 3) achieve depression remission six months after ART initiation 
compared to patients during the screening-only phase.  
AIM 3: Explain the success or failure of the program implementation using a 
mixed-methods approach. We used clinical data and in-depth interviews with patients, 
providers, and clinic leadership to describe and explain program implementation. We 
hypothesized that this mixed-methods approach would help contextualize findings from Aims 1 
and 2 and that lessons learned from this experience would inform future efforts to implement and 
evaluate integrated depression treatment programs. 
This dissertation was a unique opportunity to study real-world depression treatment and 
HIV care in a high-HIV-prevalence setting in SSA. The study employed an innovative approach, 
combining traditional epidemiologic methods with implementation science to better understand 
the effect of depression on HIV outcomes and the impact of an integrated model of HIV and 
depression treatment. This improved understanding is urgently needed and may improve 






CHAPTER II: BACKGROUND 
 
The prevalence of HIV in Malawi is one of the highest in the world at nearly 10% of the 
adult population. In 2018, an estimated 9.2% of the adult population (aged 15-49) in Malawi was 
living with HIV – approximately one million Malawians.17 That same year, 90% of people living 
with HIV in Malawi were aware of their status, 78% were on treatment, and 69% were being 
virally suppressed.17 Furthermore, women are disproportionately burdened by HIV in Malawi, a 
disparity that is especially prominent among 25- to 29-year-olds, as the prevalence among 
women in this age group (14.1%) is three time higher than among men (4.8%).18  Such a 
drastically high prevalence of HIV may play a role in the country’s low life expectancy, stress 
the health care system, and impede economic development.19 
Malawi has rapidly scaled up its HIV testing and treatment services over the past two 
decades.  Malawi was one of the first countries in sub-Saharan Africa (SSA) to adopt a “public 
health approach” to HIV scale-up, as promoted by the World Health Organization (WHO) to 
encourage rapid antiretroviral therapy (ART) initiation.20,21 The country was also an early 
adopter in 2011 of Option B+, a mother-to-child-transmission strategy in which all pregnant 
women living with HIV are provided with ART.22 Malawi now pursues a test-and-treat strategy 
in which patients found to be infected with HIV are immediately initiated on ART that same 
day.20,21 Malawi, like many other countries in the sub-Saharan region, is striving to meet the 
UNAIDS 90-90-90 goals (diagnosing 90% of all people living with HIV, providing ART to 90% 
of those diagnosed, and achieving viral suppression for 90% of those treated). Despite recent 
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improvements in ART service provision23, substantial attrition across the HIV care continuum 
continues to impede successful HIV outcomes for people living with HIV.21,24 
Early retention and continued engagement in HIV care in Malawi remains challenging. 
While great strides have been made towards controlling the HIV epidemic and engaging people 
living with HIV in care, only 76% of adults initiating ART are retained in care at 12 months, and 
only 65% are both retained in care and virally suppressed at 12 months.25  In Malawi, early 
retention in care is particularly challenging: nearly a quarter of people are lost to care during the 
first year of treatment.26-28 As such, early retention remains a major obstacle to achieving the 
UNAIDS 90-90-90 goals.26-28 Despite these retention shortfalls, research on retention in HIV 
care in Malawi has largely focused on a single population: pregnant women receiving the Option 
B+ intervention. Reasons for early attrition are among the general population living with HIV are 
not entirely understood and not well-explored. However, barriers to retention in care may include 
human resource and institutional challenges, distance to the clinic, lack of support, stigma and 
fear of HIV status disclosure, and psychiatric illnesses such as depression.24,29-31   
Depression is a major contributor to the global burden of disease and disability and is 
highly prevalent among people living with HIV in Malawi and elsewhere in SSA where mental 
health care is limited.32,33 A growing body of research is beginning to document the scope of 
mental health challenges in the general Malawian population. In Malawian primary care settings, 
28.8% of all patients have a common mental disorder, most commonly depression.34 Only a few 
studies have estimated the prevalence of depression among populations living with HIV in 
Malawi and estimates vary: 19% among adolescents attending HIV clinics35; 16% among adults 
newly initiating ART and 9% among adults on ART for at least 6 months36; and 10% of 
antenatal women and 1% to 6% of postpartum women.37  Little is known about differences in 
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experiences with or prevalence of depression between men and women in SSA. A recent 
systematic review on the prevalence and factors associated with depression among people living 
with HIV in SSA found that being female was frequently associated with depression, but there 
was no consensus.38 Worldwide, women generally have a higher prevalence of depression 
potential due to an array of social and biological factors.39,40 However, qualitative research 
suggests that traditional masculine gender norms may impact the way men experience depression 
and engage with treatment.41 Further research is needed to understand the magnitude of the 
burden of depression and unpack any gender differences in the sub-Saharan African region.  
Depression is a critical barrier to HIV care engagement. Beyond the morbidity produced 
by depression in its own right, depression is also an important barrier to early and consistent HIV 
care engagement and long-term viral suppression.1-6 A few studies conducted in SSA have found 
that depressed individuals are less likely to be linked to ART or start treatment.42-44 For example, 
one study conducted in South Africa found that depressed individuals had a higher odds of 
waiting at least three months following an HIV diagnosis to initiate ART compared to their non-
depressed counterparts.42  Depression has been consistently associated with poor adherence to 
ART.2,45  In SSA, and Malawi in particular, further evidence is needed to characterize the 
association between depression, HIV care engagement, and achievement of viral suppression.  
The mechanisms through which depression undermines successful HIV care engagement 
are not fully clear; characteristics of depression including loss of interest, poor concentration, 
poor motivation, reduced self-efficacy, fatigue, hopelessness, and suicidality are all plausible 
factors which can impair adherence and appointment attendance.2,4,46  A recent study evaluating 
the effect of depression treatment on ART adherence and HIV care appointment attendance in 
Uganda proposed a conceptual model for how depression may influence HIV care47 (Figure 
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2.1). Drawing on social cognitive theory48 and the information, motivation and behavioral skills 
(IMB) model of health behavior,49 Wagner and colleagues argue depression may influence HIV 
care adherence through its effects on self-efficacy and motivation to adhere to treatment and 
attend clinic visits.47 In order to address the burden of depression, prevent the disruption of these 
underlying determinants of HIV care engagement, and ultimately achieve the USAID 90-90-90 
targets, evidence-based depression management approaches to improve early retention in HIV 
care are needed. 
 
Figure 2.1. Conceptual framework  
 
A growing body of depression treatment programs and models of care have been 
developed for people living with HIV. A recent systematic review of depression interventions 
found that psychological and behavioral interventions were effective treatments for depression 
among people living with HIV.50 A separate systematic review and meta-analysis of 
antidepressant medication among people living with HIV found medication to also be an 
effective means of managing depression.51  Furthermore, depression treatment has been linked to 
improved ART adherence in observational studies7-9, although evidence from interventions is 
mixed.10-15 However, there are few evidence-based depression treatment programs for people 
living with HIV tailored for use in the sub-Saharan region. Among those, antidepressant and 
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psychological counseling interventions in Tanzania, Zimbabwe, Cameroon, and Uganda, among 
other countries, have demonstrated promising improvements in HIV and mental health 
outcomes.52-58 Antidepressant interventions have employed measurement-based care (MBC) 
models of antidepressant management, often relying on tricyclic antidepressants such as 
amitriptyline58,59 and imipramine,60 which have demonstrated excellent safety and efficacy 
among people living with HIV. Problem-solving therapy, which centers around teaching patients 
how to identify triggers and effectively manage stressful life events by learning or reactivating 
problem-solving skills, has also been used in the region.61  For example, a problem-solving 
therapy program called the “Friendship Bench” was effectively designed for use in Zimbabwe 
and proven to be a successful depression treatment option.62 Further investment in depression 
treatment programs effective in low-resource settings is warranted.  
Mental health care infrastructure and human resources are severely limited in Malawi; 
currently, the country contains only three operational mental health facilities, all of which are 
located in urban centers. Mental health care is considered a specialized service in Malawi and is 
offered almost exclusively at these facilities. As of 2018, there were only four fully trained 
psychiatrists in the country – approximately one psychiatrist for every 4.5 million Malawians. It 
is unlikely that it will be possible to increase the number of specialized mental health service 
providers as a means of appropriately meeting the mental health needs of the population. While 
the lack of national data demonstrating the magnitude of mental health problems has historically 
hampered efforts to secure resources for mental health care16, movement over the last several 
years suggests this trend may be changing. 
There is a growth of recognition, support, and investment in mental health by the 
Malawian government. The Malawi Ministry of Health (MOH) recently established their Non-
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Communicable Disease (NCD) and Mental Health Unit and prioritized mental health treatment 
in their 2017-2022 Malawi Health Sector Strategic Plan.63,64 The NCD and Mental Health Unit 
has since developed action plans to: 1) integrate mental health services into other general health 
services; 2) improve the capacity of general health care workers through training to diagnose and 
manage mental health conditions at different levels of care; and 3) raise awareness of mental 
health disorders and treatment among the general population through community health workers, 
teachers, religious leaders, peer educators, and the media.65 As a result of these efforts, a pilot 
program aimed at building the mental health capacity of community health workers, encouraging 
community-level mental health promotion and detection, and integrating these community health 
worker activities into the primary care setting was successfully implemented in the Zomba 
District in southern Malawi from 2010 through 2014.66-68 Despite these advances, there is an 
urgent need for further investment in mental health treatment programs to effectively realize the 
MOH’s mental health goals and address the burden of depression among people living with HIV.  
Task-shifting depression treatment programs have the potential to improve HIV care and 
mental health outcomes, in light of mental health resource limitations. Task-shifting describes a 
process of moving tasks to less specialized health workers as means of improving health care 
coverage by making more efficient use of available human resources.69 Global guidance 
recommends task-shifting approaches as a means of providing mental health services in low-
resource settings.70 The integration of mental health services into existing primary and 
community health services in resource-limited settings has gained popularity in recent years.71-73 
In sub-Saharan Africa, task-shifting approaches are seen as an effective, economical, and 
practical means of managing depression.71,74 While only a few such programs have been 
implemented in Africa,56 the Malawi Ministry of Health piloted a task-shifting program, called 
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SOAR-Mental Health (SOAR-MH), that integrated depression screening and management into 
HIV care.16 Evaluating the implementation and impact of task-shifting models of care on mental 
health and HIV care outcomes in Malawi may be key to improving comprehensive care for 
people living with HIV and provide insight into the potential for countrywide scale-up. 
Significance 
This dissertation advances understanding of depression, depression treatment, depression 
screening, and engagement in HIV care. This research quantified the association of depression 
with retention in HIV care and viral suppression (Aim 1) and evaluated the effect of depression 
treatment on HIV and depression outcomes (Aim 2). This research further examined program 
implementation and sustainability using both clinical and qualitative data (Aim 3). 
Innovation 
This was the first study conducted in Malawi to evaluate a program integrating 
depression treatment into HIV care, and findings can be used to directly inform Malawi’s mental 
health treatment efforts. There is limited mental health infrastructure and few mental health 
specialists in Malawi, as is true in many other low- and middle-income countries.16 The Malawi 
Ministry of Health piloted a program, called SOAR-Mental Health (SOAR-MH), that integrated 
depression screening and treatment into ART initiation at two public health clinics as a means to 
address the burden of depression and improve retention in care among people living with HIV.16 
This novel pilot program was the country’s first depression treatment program for people living 
with HIV and one of the few in the sub-Saharan region to use a task-shifting model to provide 
both problem-solving therapy and antidepressant depression treatment.52-56 This study is also the 
first to evaluate the impact of the program and investigate the potential benefits of this task-
shifting depression care model. Findings from this study can be used to directly inform the 
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Malawi Ministry of Health’s ongoing national strategic plans to: 1) integrate mental health 
services into other general health services; 2) improve the capacity of general health care 
workers to diagnose and manage mental health conditions at different levels of care; and 3) raise 
awareness of mental health among the general population.65 
The study employed an innovative approach, combining traditional epidemiologic 
methods with implementation science. Implementation science is a relatively new discipline, 
particularly in low- and middle-income countries.75 There is a clear need in the field of 
epidemiology to generate evidence-based practices, interventions, and policies that can readily 
(and rapidly) be adopted and integrated into routine care in public sector settings.76,77 This study 
inherently lent itself to that purpose. We used traditional epidemiological techniques that are 
grounded in implementation science; specifically, our approach aimed to evaluate the effect of 
the SOAR-MH depression treatment on HIV outcomes and the feasibility of integrating 
depression treatment into existing public HIV services. SOAR-MH project was especially unique 
in that, while the evaluation staff worked on the ground to consent patients and collect data, none 
of the evaluation staff had any clinical responsibilities or influence on the provision of HIV or 
mental health care. As such, the study yielded high-quality, policy-relevant findings on 
depression and depression management integrated into HIV care – findings which are readily 
applicable to the implementation of integrated mental health services in non-specialist settings.  
This study advances our understanding of the relationship between depression, 
depression treatment, and engagement in HIV care. The only other studies on depression in 
Malawi describe its prevalence, but fail to unpack the association between depression and HIV 
care outcomes.35-37  While depression treatment has been linked to improved ART adherence in 
observational studies7-9, evidence from interventions is mixed.10-15 An improved understanding 
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of depression treatment is urgently needed and may improve retention in HIV care, 
psychological wellbeing, and ultimately reduce mortality for people living with HIV. This study 
addressed this knowledge gap by generating evidence on the effect of depression on retention in 
HIV care and the potential impact of depression treatment on depression and mental health 
outcomes. Such evidence may be critical for allocating resources to optimize HIV and mental 





CHAPTER III: METHODS 
 
Overview  
The goals of this dissertation were to: estimate the association between depression at 
antiretroviral therapy (ART) initiation and retention in HIV care and viral suppression (Aim 1); 
evaluate the impact of a depression treatment on depression, retention in HIV care and viral 
suppression (Aim 2); and explain the implementation of the program (Aim 3; Figure 3.1). 
 
Figure 3.1. Model for dissertation aims 
  
Parent Study 
This study consisted of secondary analyses of existing data from the SOAR-MH 
evaluation study. SOAR-MH is a Malawi Ministry of Health pilot program that integrates 
depression screening and treatment into ART care at two clinics in Malawian capital of 
Lilongwe, where 10% of the population is HIV-positive.78,79 These clinics, which offer health 
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care free of charge, are nested within two semi-urban primary-level health centers under 
Lilongwe District Health Management, in the Central Region of Malawi. One health center 
serves a catchment population of 63,783 adults and children while the other has a catchment 
population of 212,160 adults and children. However, anyone can receive health services at either 
facility, regardless of their residence. Both sites use electronic medical record (EMR) systems 
and host non-governmental partners that provide technical supervision and support, similar to 
what is seen at other public health facilities across the country.16 
The program was implemented using a multiple baseline design in two phases: a 
screening-only “control” phase and a treatment “intervention” phase (Figure 3.2). In-depth 
interviews were conducted first during the screening phase (round 1) and then again after the 
launch of program (round 2).   
 




During the screening phase, HIV care providers screened patients for depression and 
monitored their depressive symptoms using the Patient Health Questionnaire-9 (PHQ-9). The 
PHQ-9 is a widely used nine-item instrument that assesses the presence of nine symptoms of 
depression within the previous two weeks as specified by the Diagnostic and Statistical Manual 
of Mental Disorders-5 (DSM-5).80 The PHQ-9 was chosen because it focuses specifically on 
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depression, has been widely used and validated in many different settings81, and works well both 
as a screening tool for depression as well as a longitudinal measure to monitor response to 
treatment. This tool has been validated for use in HIV-positive populations in other countries in 
the region.82,83 Each of the nine items is scored as present from 0 (not at all) to 3 (nearly every 
day). A total score of 5-9 is considered indicative of mild depression, and a score of 10 or higher 
is considered indicative of moderate to severe depression (Table 3.1).84  
 
Table 3.1. PHQ-9 score interpretation and resulting treatment 
Score Depressive Symptoms Screening Phase Intervention Phase 
0-4 No or minimal No treatment No treatment necessary 
5-9 Mild Clinician counseling or referral 
to psychiatric nurse or facility* 
Problem-solving therapy 
≥10 Moderate to severe Clinician counseling or referral 
to psychiatric nurse or facility* 
Antidepressants 
Note: *Standard of care prior to the launch of the treatment program. 
 
 
During the screening phase (Figure 3.3), the HTC counselors screened patients who test positive 
for HIV with the first two questions of the PHQ-9 – known as the Patient Health Questionnaire-2 
(PHQ-2) – which capture depressed mood and anhedonia, the two core symptoms of depression. 
Only patients who scored above 0 on the PHQ-2 were then assessed for the presence of the 
remaining seven symptoms of the PHQ-9 by the ART nurse or clinician during ART initiation. 
ART providers managed patients identified with depression using existing “standard of care” 
pathways, which could include counseling by the clinician, referral to an on-site or off-site 
psychiatric nurse or other mental health specialist, or in acute cases, transport to the outpatient 
psychiatric unit at the nearby district hospital. 
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Figure 3.3. Depression screening during the screening “control” phase 
 
 
During the intervention phase (Figure 3.4), patients continued to be screened with the PHQ-9, 
but with an important difference. At the launch of this intervention phase, HIV care providers 
received additional training in depression management using an algorithm-guided module that 
utilizes PHQ-9 scores. Clinic-based lay health workers received training on Friendship Bench 
problem-solving therapy, a type of cognitive-behavioral counseling. As part of this module, 
providers used a PHQ-9 score algorithm to 1) prescribe antidepressants and manage dosage 
changes using a measurement-based care (MBC) protocol or 2) refer patients for Friendship 
Bench problem-solving therapy. Specifically, providers treated moderate to severe cases of 
depression with amitriptyline or fluoxetine using MBC. MBC is a resource-efficient, task-
sharing model for prescribing antidepressant management in non-psychiatric settings that has 
demonstrated safety, feasibility, and acceptability as part of HIV care when delivered by non-
specialists in Africa.58-60 Providers referred mild cases of depression to lay health workers. These 
lay health workers treated mild depression with Friendship Bench problem-solving therapy, a 
cognitive-behavioral counseling strategy originally developed in Zimbabwe that teaches patients 
how to identify triggers and effectively manage stressful life events by learning or reactivating 




Figure 3.4. Depression screening during the treatment “intervention” phase  
 
Study Population 
To evaluate the program, clinical data was abstracted from consenting non-pregnant 
adults (age ≥ 18) who tested positive for HIV and initiated care at one of the program sites 
between April 2017 and November 2018 both with (PHQ-9 ≥ 5) and without (PHQ-9 <5) 
depressive symptoms (Table 3.2). Across both study phases (i.e., the screening-only “control” 
phase and the active “intervention” phase), the evaluation enrolled a total of 2067 patients.  
 
Table 3.2. Study populations included in each aim 
Phase Enrolled: 
Quantitative Qualitative 
Screening Treatment Screening Treatment 
PHQ-9 Score* ≥ 5 < 5 ≥ 5 < 5 n/a n/a 
Number of participants 290 852 212 724 24 26 
 Included in Aim 1    
   
 












Notes: *PHQ-9 ≥ 5 is indicative of elevated depressive symptoms. PHQ-
9=Patient Health Questionnaire-9. 
 
 
Only patients who completed depression screening at baseline were included in these analyses. 
Aims 1 (association between depression and successful HIV treatment retention) and 2 
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(depression treatment program evaluation) consisted of analyses of data from patients enrolled 
during the SOAR-MH program evaluation. Aim 3 (mixed-methods assessment of program 
implementation) used data from patients enrolled during the program evaluation as well as 
qualitative data from the second round of in-depth interviews with patients, Friendship Bench 
counselors, ART providers, and clinic leadership.  
Data Collection and Abstraction 
This study relied on the abstraction of routinely collected clinical data on depression 
screening and HIV care from consenting participants’ ART clinical records over a 13-month 
period, starting at ART initiation. At the study sites, when a patient initiates ART, clinic staff 
create a paper medical chart (called an ART mastercard) and accompanying electronic medical 
record for the patient where HIV care data will be recorded. 
Additionally, two rounds of in-depth interviews were conducted with patients and health 
care facility staff at both sites, the first round during the screening-only control phase and the 
second during the intervention phase. Prior to both rounds of data collection, evaluation staff met 
with administrators at both health centers and drew up a list of staff. The program coordinator or 
interviewer approached staff and leadership at each clinic to schedule interviews. The research 
assistants identified patients returning for ART services and invited these patients to participate. 
An effort was made to interview both men and women, as prior research has shown attitudes 
towards depression and the provision of mental health care may vary by gender in both providers 
and patients.85-87  
The research team developed semi-structured interview guides to evaluate the 
implementation at different stages of the program. The first interview guide focused on 
experiences with the depression screening and care during the screening-only phase. The second 
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interview guide focused on experiences during the intervention phase, specifically with MBC or 
the Friendship Bench. Interviews were conducted in either Chichewa (the local language) or 
English, based on participants’ preference, by two different Malawian women with backgrounds 
in qualitative research and HIV care services. All interviews were held at the respective clinics in 
a private location. The interviews were audio-recorded and transcribed as follows: The first 
round of qualitative interviews was directly translated and transcribed into English. The second 
round of qualitative interviews was transcribed in Chichewa and then translated into English. 
The research team reviewed transcripts as they became available and provided feedback to the 
interviewers throughout the data collection process to ensure quality.  
Measures 
This dissertation draws on abstracted clinical data from consenting participants. During 
the program evaluation, research assistants abstracted routinely collected clinic data on 
depression and HIV care from consenting participants’ clinical records over a 13-month period, 
starting at ART initiation. Abstracted data included appointment dates, expected return dates, 
ART pills dispensed, PHQ-9 scores, and depression treatment provided. Additionally, data on 
age, sex, clinic, World Health Organization (WHO) disease stage88, village of residence, ART 
medication prescribed, and presence of baseline suicidality were abstracted. 
Depression at ART Initiation 
Depression at ART initiation was measured with the PHQ-9. Elevated depressive 
symptoms suggesting a high risk of a depressive disorder was defined as a PHQ-9 score ≥5 at 
ART initiation.89 We also considered a 3-level depressive severity measure (0-4, 5-9, and ≥10, 
corresponding to no depression, mild depression, and moderate to severe depression, 
respectively) and a continuous measure of depressive severity (range 0-27).   
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Retention in Care 
The following metrics were used to measure retention in care:  
Continuous engagement in care was defined as never being more that 14 days late to an 
appointment through six months in care.   
Alive and in care at six months was defined as being on ART for at least some portion of 
the two months prior to the six-month anniversary of starting ART, in alignment with Malawi 
Ministry of Health reporting practices. According to the Malawi Guidelines for Clinical 
Management of HIV in Children and Adults, an ART patient is classified as a defaulter if they go 
two months without ART based on the pill provided at their most recent appointment.90 Patients 
who are not known to have transferred, stopped ART, or died are classified as alive and on ART.  
Currently on ART at six months was defined as currently having ART on hand at six 
months, i.e., attending an appointment prior to the six-month point and receiving a supply of 
ART that would last through the six-month point. For example, if a participant attended an 
appointment five and a half months after starting ART and received a 30-day supply of ART, 
they would have been considered currently on ART at six months. This indicator aligns closely 
with the PEPFAR definition of “currently on treatment.”91 
In care after six months was defined as attending at least one appointment where ART is 
provided after six months in care. This definition aligns more closely with the UNAIDS Global 
AIDS Monitoring 2019 Indicators by identifying participants known to be on ART at some point 
six months after initiation.92  
HIV appointment attendance was defined as the proportion of scheduled HIV 
appointments attended within one week of the scheduled appointment date in the first six months 
of care.93  
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Consistent ART was defined as never going more than five days without ART in the first 
six months, calculated from the cumulative days’ supply of ART dispensed at each appointment 
in the first six months and the time between appointments.  
ART pill possession ratio was defined as the proportion of the first six months (183 days) 
since ART initiation with ART in hand, calculated from cumulative pills dispensed at each ART 
appointment through six months.94  
Viral Suppression 
We defined viral suppression as a viral load <1,000 copies/mL drawn at least five and a 
half months (166 days) after starting ART, following the 2018 Malawian ART guidelines. Viral 
load testing was performed at Bwaila Hospital in Lilongwe using collected plasma or dried blood 
spots and processed by Abbott m2000 RealTime HIV-1 assay instruments.95  
Depression Remission 
Depression remission was defined as a PHQ-9 score of less than 5 taken after at least five 
and a half months (166 days) in care, to allow for completion of the acute phase of treatment and 
maintenance of that response.96   
Other Covariates 
 Potential confounders included in the Aims 1-2 analyses included age (in years), sex, 
clinic, World Health Organization (WHO) HIV clinical stage for HIV surveillance (I-IV)88, 
village of residence, ART medication prescribed, and presence of baseline suicidality. Village of 
residence categorized individuals as residing in urban Lilongwe City, in rural Lilongwe District, 
or outside of Lilongwe District. Presence of suicidal thoughts was defined as any endorsement of 
the ninth question of the PHQ-9: “During the past two weeks, how many days have you been 
bothered by thoughts that you would be better off dead or of hurting yourself in some way?”  
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Data Analyses 
All analyses were performed using STATA IC 14 or NVivo (Version 12). 
Aim 1: Analysis 
We completed unadjusted, tabular comparisons of HIV care outcomes by depressive 
severity. We used log-binomial models to estimate adjusted risk ratios comparing the probability 
of each binary HIV care outcome among those with depression compared to those without. For 
the continuous outcomes, we used ordinary least-squares linear regression models to estimate 
mean differences. Potential confounders were identified through directed acyclic graph (DAG) 
analysis.  
To address missing outcome data for those who transferred to a non-study facility or who 
returned for care around six months but did not get a viral load, we used multiple imputation by 
chained equations (MICE) to fill missing values using logistic regression imputation methods97.  
Aim 2: Analysis 
The main analysis followed an “intent-to-treat” approach, classifying participants 
according to the phase during which they initiated ART (i.e., to either the screening-only 
“control” group or the active “intervention” group) without regard to actual treatment received. 
We first completed unadjusted, tabular comparisons of HIV care and depression outcomes in the 
intervention group relative to the control group. We then used log-binomial models to estimate 
adjusted risk ratios comparing the probability of the primary outcome, i.e. retention with viral 
suppression, as well as the probability of other secondary HIV care outcomes in the intervention 
group compared to the control group. To separately evaluate the impact of the Friendship Bench 
therapy and the antidepressant treatment, we then stratified the main analysis by depressive 
severity at baseline (mild or moderate-to-severe depressive symptoms). Other secondary 
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analyses used a “treatment started” approach, comparing those who actually started Friendship 
Bench therapy or antidepressants to those who did not in both phases, and then an “as treated” 
approach, comparing those who received at least two Friendship Bench therapy sessions or two 
months of antidepressants to patients who did not in both phases, restricted to only those who 
attended at least their first follow-up visit. 
 To address missing outcome data due to transferring to a non-study site facility for HIV 
care, we used multiple imputation by chained equations (MICE) to fill missing values using 
logistic regression imputation methods. 97  
Aim 3: Analysis 
 Using clinically abstracted data, participants were classified by the phase during which 
they initiated ART treatment, i.e., to either the screening-only “control” or active “intervention” 
group. We completed tabular comparisons of participants’ depression treatment data to describe 
the implementation of the program.  
Only the second round of qualitative data was analyzed as part of this aim. After reading 
each of the transcripts, the doctoral candidate (MS) drafted a thematic codebook that addressed 
the study objectives and captured emerging themes evident from her initial review of the 
transcripts.98,99 As such, many codes were developed a priori, given that the interview questions 
were linked to the program implementation, while others were developed a posteriori. MS then 
met with research team members who had simultaneously been reviewing the transcripts to 
review and finalize the codebook. Two coders (MS and an additional second coder) coded a 
subset of the same transcripts to ensure consistency in their use of the codes using NVivo 
(Version 12). Coding was treated as an iterative process and the coders met several times 
throughout to discuss the addition, definition, and appropriate use of the codes that emerged from 
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the data. Additionally, the coders wrote memos for the individual transcripts and on emerging 
themes. Upon completion of coding, MS executed queries in NVivo and both she and the second 
coder reviewed coded data related to the key aspects of program implementation: depression 
treatment initiation, depression treatment over time, program impact, and program sustainability. 
While synthesizing these findings, MS met with the research team to ensure accurate 




CHAPTER IV: ASSOCIATION BETWEEN DEPRESSION AND HIV CARE 




The prevalence of HIV in sub-Saharan countries such as Malawi is among the highest in 
the world.17,100 Like many other countries in the region, Malawi has adopted a “public health 
approach” to HIV scale-up in order to meet the UNAIDS 90-90-90 goals (diagnosing 90% of all 
people living with HIV, providing antiretroviral therapy [ART] to 90% of those diagnosed, and 
achieving viral suppression for 90% of those treated).20,21,101 Great strides have been made 
towards achieving these goals and engaging people living with HIV in care across the 
region102,103; in 2018 in Malawi, 90% of those living with HIV were estimated to be aware of 
their status, 87% of those aware of their status were on treatment, and 89% of those on treatment 
were virally suppressed.17 Despite recent improvements in ART service provision, both linkage 
to care and continued engagement in HIV care in sub-Saharan Africa (SSA) remain 
challenging104,105; improving retention in HIV care will be crucial to attaining the 90% on ART 
target in the sub-Saharan region.104,106 The reasons for attrition among people living with HIV 
are not entirely understood, though barriers to retention in care may include human resource and 
institutional challenges, distance to the clinic, lack of support, stigma and fear of HIV status 
disclosure, and psychiatric illnesses such as depression.24,29-31 
Depression is a major contributor to the burden of disease and disability and is highly 
prevalent among people living with HIV in Malawi and elsewhere in SSA, a region where 
mental health care is often limited.32,33 Depression affects 18% to 30% of patients receiving HIV 
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care in Africa,1 and estimates from Malawi range from 1% to 19%.35-37,107 The high prevalence 
of depression among people living with HIV is thought to be due to coping with the HIV 
diagnosis, disease symptoms, bereavement, relationship crises, stigma and discrimination, co‐
existing poverty, ART side effects, fear of death, and infection-related inflammatory 
processes108,109. Depression can result in reduced quality of life, decreased economic 
productivity, social isolation, and cognitive decline.108,109 Among people with HIV, depression 
has the potential to worsen HIV-related morbidity and mortality, particularly in low-resource 
settings.   
Depression has been shown to be an important barrier to linkage to care, retention, ART 
adherence and ultimately long-term viral suppression across the globe.1-6,110 A bourgeoning body 
of research in SSA is beginning to demonstrate that depressed individuals are less likely to be 
linked to ART care or start ART.42-44 Further, depression is also associated with poor adherence 
to ART in SSA.1,2,45 However, limited research has been conducted in SSA on the association 
between depression and consistent retention in HIV care and viral suppression. As such, further 
evidence is needed to characterize the association between depression, HIV care engagement, 
and achievement of viral suppression is the sub-Saharan region.  
This analysis addresses this knowledge gap by generating evidence on the association of 
depression with two key HIV care outcomes: retention in HIV care and viral suppression. 
Compared to those without depressive symptoms, we hypothesized that those with elevated 
depressive symptoms at ART initiation would be less likely to be retained in HIV care and to be 




This study is nested within the first phase of a pilot program that integrated depression 
screening and treatment into routine HIV primary care using existing staff at two public health 
clinics in Lilongwe, Malawi, that employed a staggered, multiple baseline design.111 We 
implemented this program in two staggered phases – a depression screening-only phase and a 
depression treatment intervention phase (Figure 4.1). During the screening-only phase, HIV 
testing and counseling (HTC) counselors screened all patients newly diagnosed with HIV for 
depressed mood or anhedonia using the Patient Health Questionnaire-2 (PHQ-2), or the first two 
questions of the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a nine-item 
questionnaire that assesses the presence and frequency of the nine Diagnostic and Statistical 
Manual of Mental Disorders symptoms of major depression.80 It has been widely used in the sub-
Saharan region.82,83,112 For patients who endorsed the PHQ-2, the ART clinician then 
administered the remaining seven PHQ-9 questions during ART initiation.  A total score of 5-9 is 
considered indicative of mild depression and a total score of 10 or above is considered indicative 
of moderate-to-severe depression.84 During the screening-only phase, patients who were 
identified with elevated depressive symptoms were managed by clinicians using existing care 
options within the Malawi primary care system. These options theoretically included counseling, 
antidepressants or referral to an on-site or off-site mental health specialist, or in acute cases, 
transport to the outpatient psychiatric unit at the nearby district hospital. However, in practice, 
counseling consisted of informal counseling by the ART provider and antidepressants were 




Figure 4.1. Program implementation 
 
Population 
All non-pregnant adults (18 years or older) newly initiating ART at the study sites were 
eligible to be enrolled in the program evaluation. Research assistants approached such 
individuals awaiting ART initiation to invite them to participate in the study and nearly all (98%) 
provided informed consent. This analysis is restricted to consenting individuals who completed 
depression screening during the screening-only phase of the program, e.g., only those who 
initiated care between April 2017 and October 2017 at Clinic A and between April 2017 and 
March 2018 at Clinic B (Figure 4.1).  
Data Collection and Abstraction 
This study relied on the abstraction of routinely collected clinical data on depression 
screening and HIV care from consenting participants’ ART clinical records over a 13-month 
period, starting at ART initiation. At the study sites, when a patient initiates ART, clinic staff 
create a paper medical chart (called an ART mastercard) and accompanying electronic medical 
record for the patient where HIV care data will be recorded. At each appointment, the clinicians 
schedule the next follow-up appointment and provide the patient with a supply of ART that will 
last until their next appointment. ART pills are provided in increments of 30. Generally, for the 
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first six months of care, newly initiating ART patients are scheduled to come monthly, though 
exceptions can be made and a larger supply of ART can be provided.  
Measures 
Depression at ART Initiation 
Elevated depressive symptoms suggesting a high risk of a depressive disorder (hitherto 
described as “depression”) was defined as a PHQ-9 score ≥5 at ART initiation, following the 
definition in the parent study89. We also consider a 3-level depressive severity measure (0-4, 5-9, 
and ≥10, corresponding to no, mild, and moderate to severe depression, respectively) and a 
continuous measure (range 0-27) of depressive severity.   
Viral Suppression 
We defined viral suppression as a viral load <1,000 copies/mL drawn at least five and a 
half months (166 days) after starting ART, following the 2018 Malawian ART guidelines. Viral 
load testing was performed at Bwaila Hospital in Lilongwe using collected plasma or dried blood 
spots and processed by Abbott m2000 RealTime HIV-1 assay instruments.95  
Retention in HIV Care 
We constructed several measures to capture retention in HIV care through six months in 
care. Some measures were constructed specifically for this analysis, while others were 
constructed in alignment with nationally and internationally recognized measures of retention.  
Continuous engagement in care was defined as never being more that 14 days late to an 
appointment through 6 months in care.   
Alive and in care at six months was defined as being on ART for at least some portion of 
the two months prior to the six-month anniversary of starting ART, in alignment with Malawi 
Ministry of Health reporting practices. According to the Malawi Guidelines for Clinical 
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Management of HIV in Children and Adults, an ART patient is classified as a defaulter if they go 
two months without ART based on the pill provided at their most recent appointment.90 Patients 
who are not known to have transferred, stopped ART, or died are classified as alive and on ART.  
Currently on ART at six months was defined as currently having ART on hand at six 
months, i.e. attending an appointment prior to the six-month point and receiving a supply of ART 
that would last through the six-month point. For example, if a participant attended an 
appointment five and a half months after starting ART and received a 30-day supply of ART, 
they would have been considered currently on ART at six months. This indicator aligns closely 
with the PEPFAR definition of “currently on treatment.”91 
In care after six months was defined as attending at least one appointment where ART is 
provided after six months in care. This definition aligns more closely with the UNAIDS Global 
AIDS Monitoring 2019 Indicators by identifying participants known to be on ART at some point 
six months after initiation.92  
HIV appointment attendance was defined as the proportion of scheduled HIV 
appointments attended within one week of the scheduled appointment date in the first six months 
of care.93  
Consistent ART was defined as never going more than five days without ART in the first 
six months, calculated from the cumulative days’ supply of ART dispensed at each appointment 
in the first 6 months and the time between appointments.  
ART pill possession ratio was defined as the proportion of the first six months (183 days) 
since ART initiation with ART in hand, calculated from cumulative pills dispensed at each ART 
appointment through six months.94  
Retention + Viral Suppression  
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A combined outcome of continuous engagement in HIV care with viral suppression six 
months after starting ART was defined as meeting both of the following criteria: never being 
more than 14 days late to a scheduled HIV appointment through six months in care and having a 
viral load <1,000 copies/mL drawn at least five and a half months (166 days) after ART 
initiation.  
Variables of Interest 
Due to the data collection design of this study, only routinely collected clinical data was 
captured including age, sex, clinic, World Health Organization (WHO) HIV clinical stage for 
HIV surveillance (I-IV) 88, village of residence, and ART medication prescribed. Village of 
residence was used to categorize individuals as residing in urban Lilongwe City, in rural 
Lilongwe District, or outside of Lilongwe District. Baseline CD4 and viral load are not collected 
in the Malawi public health system as the policy encourages a “test and treat” strategy; 
individuals who test positive for HIV are initiated on ART irrespective of CD4 and viral load.   
Analysis 
We first completed unadjusted, tabular comparisons of HIV care outcomes by depressive 
severity (none, mild, and moderate to severe). We then used log-binomial models to estimate 
adjusted risk ratios comparing the probability of each binary HIV care outcome among those 
with depression compared to those without. For the continuous outcomes, we used ordinary 
least-squares linear regression models to estimate mean differences. Potential confounders were 
identified through directed acyclic graph (DAG) analysis.  
To address missing outcome data for those who transferred to a non-study facility or who 
returned for care around six months but did not get a viral load, we used multiple imputation by 
chained equations (MICE) to fill missing values using logistic regression imputation methods.97 
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We imputed values based on the covariates included in the final model. We generated 15 
imputed datasets to ensure the number of imputed datasets was at least as large as the percentage 
of incomplete information for the main outcome, “continuous engagement with viral 
suppression.”113 Finally, we confirmed that the number of imputed datasets was also larger than 
the parameter-specific fraction of missing information for all parameters included in the final 
model.114 
 All analyses were performed using STATA IC 14.   
Ethical Review 
The National Health Sciences Research Committee of Malawi (NHSRC) and the 
Biomedical Institutional Review Board (IRB) of the University of North Carolina at Chapel Hill 
approved the study protocol.  All participants underwent a consent process during ART initiation 
and gave written informed consent to allow the abstraction of their clinical data.  
Results  
Participant Characteristics 
Of 1091 participants screened, 601 (55%) screened negative on the PHQ-2; the full PHQ-
9 was administered to the remaining 490 (Table 4.1). Of these, 291 (27% of those enrolled) 
endorsed symptoms consistent with our operational definition of depression (PHQ-9 score ≥5). 
Of these, 74% had mild depression (PHQ-9 scores 5-9) and 26% had moderate to severe 
depression (PHQ-9 scores ≥ 10). Just over half of all participants were female; those with 
depression were slightly more likely to be female than those without. The mean age of 
participants was 33.5 years and did not vary appreciably between participants with and without 
depression. Nearly all participants were classified as asymptomatic (Stage I) for HIV at ART 
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initiation and were initiated on a combination of tenofovir, lamivudine, and efavirenz 
(TDF/3TC/EFV).  
 
Table 4.1. Participant characteristics (N=1091)  






Baseline Depressive Severity    
   Screen-negative (PHQ-2: 0) 601 (29%) 601 (75%) N/A 
   Minimal (PHQ-9: 1-4) 199 (18%) 199 (25%) N/A 
   Mild (PHQ-9: 5-9)  215 (20%) N/A 215 (74%) 
   Moderate (PHQ-9: 10-19)  71 (7%) N/A 71 (24%) 
   Severe (PHQ-9: 20-27)  5 (<1%) N/A 5 (2%) 
Sex 
   
   Male 513 (47%) 387 (48%) 126 (43%) 
   Female 578 (53%) 413 (52%) 165 (57%) 
Age 33.5 (9.6) 33.4 (9.4) 33.6 (10.1) 
Residence*    
  Urban Lilongwe 976 (93%) 717 (93%) 259 (93%) 
  Rural Lilongwe 54 (5%) 40 (5%) 17 (6%) 
  Outside Lilongwe District 17 (2%) 15 (2%) 2 (1%) 
WHO Disease Stage 
   
   I 1089 (>99%) 800 (100%) 289 (99%) 
   II-IV 2 (<1%) 0 (0%) 2 (1%) 
Baseline ART prescription**    
  TDF/3TC/EFV 1078 (99%) 790 (99%) 288 (99%) 
  Other 12 (1%) 9 (1%) 3 (1%) 
Clinic    
   Clinic A 435 (40%) 319 (40%) 116 (40%) 
   Clinic B 656 (60%) 481 (60%) 175 (60%) 
Notes: *Missing n=44. **Missing n=1. ART=antiretroviral therapy. PHQ-2=Patient Health Questionnaire 2. PHQ-
9=Patient Health Questionnaire-9. TDF/3TC/EFV=tenofovir, lamivudine, and efavirenz. 
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HIV Care Outcomes: Retention in Care and Viral Suppression 
The HIV care outcomes measures did not vary appreciably between those without, with 
mild, and with moderate to severe depression (Table 4.2). Regardless of metric, retention in HIV 
care was generally low. Using the Malawi Ministry of Health ART patient classification, around 
60% of participants would have been classified as alive and in care at 6 months. Around 50% 
were currently on ART at 6 months and around 40% attended an appointment after 6 months and 
maintained a consistent supply of ART through 6 months. While only 45% (N=454) of patients 
who had not transferred or died had viral loads drawn; nearly all of those were virally 
suppressed. Only around 23% of participants achieved both continuous engagement and viral 
suppression. 
 









 % or Mean (SD) 
Retention Indicators N=1017 N=750 N=200 N=67 
 Continuous engagement 30%  28% 34% 34% 
 Alive and in care 58% 57% 63% 58% 
 Currently on ART 48% 46% 53% 48% 
 In care after 6 months 43% 43% 43% 39% 
 Consistent ART 40% 40% 43% 42% 
 HIV appointment attendance (Range: 0-1) 0.5 (0.4) 0.5 (0.4) 0.6 (0.4) 0.5 (0.4) 
 ART pill possession (Range: 0.16-1),  0.7 (0.4) 0.7 (0.4) 0.7 (0.3) 0.7 (0.4) 
Viral suppression N=454 N=339 N=88 N=27 
 Viral suppression 93%  93% 94% 93% 
Retention + Viral Suppression N=945 N=698 N=186 N=61 
  Continuous engagement with viral suppression 23% 21% 28% 26% 
Notes: This table does not include data on individuals who transferred within the first 6 months of care: Not 
Depressed n=48; Mild Depression n=15; Moderate to Severe Depression n= 9; Died within the first 6 months of 
care: Not Depressed n=2. Denominators vary due to viral loads not being drawn or not having or attending a 
scheduled appointment around 6 months. ART=antiretroviral therapy. 
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The final adjusted model controlled for clinic and sex. As a continuous variable, age 
introduced model instability and was removed from the final adjustment set as age did not appear 
to be associated with any of the outcomes or depression at baseline. WHO stage, ART 
medication, and area of residence did not vary enough to be considered potential confounders. 
Addressing missing data through multiple imputation did not appreciably change any of the 
results.   
After adjustment, depression at ART initiation did not appear to be significantly 
associated with any of the HIV care outcomes (Table 4.3). 
 
Table 4.3 Association of depression (PHQ-9≥5) at ART initiation with HIV care outcomes 
Outcome  Unadjusted Adjusted Imputation 
 RR (95% CI) 
Retention Indicators    
 Continuous retention 1.21 (0.99-1.48) 1.15 (0.95-1.4) 1.16 (0.96-1.4) 
 Not a defaulter 1.08 (0.97-1.21) 1.08 (0.97-1.21) 1.09 (0.98-1.21) 
 Currently on ART 1.11 (0.97-1.28) 1.11 (0.97-1.27) 1.11 (0.97-1.27) 
 Retention in care 1.03 (0.91-1.16) 1.04 (0.93-1.17) 1.04 (0.93-1.17) 
 Consistent ART 1.06 (0.89-1.25) 1.05 (0.89-1.23) 1.05 (0.89-1.23) 
Retention + Viral Suppression    
 Continuous retention with viral suppression 1.27 (0.99-1.63) 1.21 (0.95-1.53) 1.18 (0.97-1.44) 
 Mean Difference (95% CI) 
 HIV appointment attendance (Range: 0-1) 0.03 (-0.02-0.08) 0.03 (-0.02-0.08) 0.06 (-0.00-0.12) 
 ART pill possession (Range: 0.16-1) 0.01 (-0.04-0.06) 0.01 (-0.04-0.06) 0.02 (-0.03-0.06) 
Notes: ART=antiretroviral therapy. PHQ-9=Patient Health Questionnaire-9.  
 
Discussion 
While the prevalence of depression among this population of adults newly initiating ART 
was high at 27%, those with depression had similar HIV care outcomes at six months compared 
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to those without depression. Retention metrics were generally poor for both groups. However, 
among those sent for viral load testing, nearly all achieved viral suppression.  
The influence of depression on retention in HIV care is complicated. Several recent 
reviews and meta-analyses have documented the association between depression and ART 
adherence2,115, though the relationship between depression and engagement in HIV care or 
retention is less well understood. We hypothesized that depression could plausibly impair 
adherence and appointment attendance as depression often manifests through loss of interest, 
poor concentration, poor motivation, reduced self-efficacy, fatigue, hopelessness, and 
suicidality.2,4,46 However, in our study population, depression was not associated with any of the 
retention indicators or viral suppression at six months. Several studies conducted in South 
Africa, Kenya, and Uganda examining the association between depression prior to HIV testing 
and linkage to care had mixed results.44,116,117  In South Africa, where linkage to care was defined 
as obtaining a CD4 count within three months of a positive HIV test, one study found no 
difference between those with and without depression at testing116 and one found that those with 
depression were less likely to be linked to care.44 In Kenya and Uganda, greater depressive 
symptom severity was associated with greater likelihood of ART initiation during the study 
period among sero-converted partners of previously sero-discordant couples.117 Studies of 
depression and retention in care conducted in Malawi and the Democratic Republic of the Congo 
found no difference between 12-month retention or viral suppression among pregnant women 
with and without depression at ART initiation.37,118 One explanation for the differences in the 
literature relating depression and ART adherence versus relating depression and retention is that 
depression may not affect engagement in care in the same way it impacts ART adherence; 
different skills sets are required for adherence to daily ART versus maintaining monthly clinic 
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visits.116 Further efforts to understand the relationship between depression and HIV will need to 
unpack the mechanisms through which depression impacts the different aspects of HIV care 
engagement.  
Nonetheless, the lack of association between depression at ART initiation and any of the 
HIV outcomes in this study population is striking. Qualitative interviews with providers and 
patients conducted within the larger parent study during the screening phase of the program, 
suggest that individuals identified with depression during the screening phase possibly received 
additional counseling on accepting their HIV status, ART adherence, and managing their 
depression.119 While these participants with depression did not receive evidence-based 
standardized depression treatment, it is possible that this additional attention may have acted as 
an informal intervention. As such, this additional attention may have had a positive impact on 
HIV care engagement for depressed patients included in this analysis relative to those without 
depression.  
Locally adapted, valid depression diagnostic and management tools are vital for 
addressing the burden of depression among people living with HIV. The implementation team 
chose the PHQ-9 for use among people living with HIV because it focuses specifically on 
depression, has been widely used and validated in many different cultures (including among 
people living with HIV in SSA)81-83, and works well both as a case identification tool as well as a 
longitudinal monitor of response to treatment. However, at the time, the PHQ-9 had yet to be 
validated in Malawi, though it has since undergone validation among a population of patients 
with diabetes.120 Along that vein, cases of “depression” were identified with the PHQ-9 
screening tool and not a diagnostic interview. It is plausible that some depressive symptoms were 
not actually features of a major depressive episode, but rather a manifestation of milder 
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syndromes, more likely to resolve spontaneously and not require an intervention. Furthermore, 
the PHQ-9 was originally developed to be self-administered, but was administered by providers 
due to low levels of literacy among the patient population. Given the overlap in symptomology 
between HIV and depression itself, HIV providers may have identified an inaccurate burden of 
depression among people living with HIV.121 As this study relied on existing staff to screen 
patients for depression who were not incentivized to engage in the depression screening program, 
it is also possible that providers underdiagnosed cases of depression. While a small sub-study 
comparing the providers’ administration of the PHQ-9 to that of trained research assistants did 
find that research assistants identified more cases of depression than providers, there was still 
high overall agreement between providers and research assistants.122 Nevertheless, the accuracy 
of the PHQ-9 may have been compromised, given the mode of administration, i.e., 
administration by existing staff with varying degrees of commitment to the program as opposed 
to self-administered. Tools such as the PHQ-9 would benefit from further quantitative validation 
against a “gold standard” diagnostic instrument to confirm their utility as part of task-shifting 
programs in SSA, particularly among people living with HIV. 
Finally, complexities in measuring engagement and retention in HIV further complicate 
the study of the role of depression in HIV care. Despite the importance of retention to 
successfully treating HIV, there is no recognized “gold standard” measure for retention in care.93 
A recent meta-analysis highlighted some of the challenges around comparing studies examining 
the association between mental health disorder diagnoses and retention in HIV care, noting that 
“retention in care” may be operationalized to include measures of visit constancy, kept visits, no-
show rates, and gaps in care.110 In this study, retention overall was very low; only 30% of all 
participants remained continuously engaged in care through six months and only 43% attended 
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an appointment after six months in care. Using Malawi’s definition of retention, overall 58% of 
participants were considered alive and in care at six months, though this is still lower than 
Malawi’s 2018 12-month retention estimates which found that 72% of adults who initiated ART 
were still in care at 12 months.123 It is possible that we potentially underestimated retention in 
care due to “silent transfers,” or individuals who decided to access care at a different location 
without formally transferring their records. In fact, the Malawi Ministry of Health assumes that 
actual retention is about 10% higher due to this misclassification of “silent transfers” as 
“defaulters” in clinic-based retention analysis, though a meta-analysis of low- and middle-
income country studies suggests retention may be as much as 18% higher.124  Recognizing that 
this misclassification could have influenced all of the HIV care engagement measures, the rate of 
silent transfer should not have varied between groups, so “silent transfers” should not have 
significantly biased comparisons between those with and without depression.123 In this sense, 
“retention” in our study is tantamount to “retention at the specific clinic,” and the data available 
may not yield a complete picture of engagement in care, limitations often faced by studies on 
retention in HIV care in SSA.125,126 Innovative methods and approaches for measuring retention 
in care to manage these complexities are needed, particularly in low-resource settings.  
Limitations 
Due to the implementation science nature of this study, the covariates captured were 
limited to routinely collected clinical data. It is possible that the presented analyses were biased 
by unmeasured confounding factors. It is also possible that we overestimated viral suppression, 
as viral loads could only be drawn from patients who remained in care and a large proportion of 
patients who did return for care were never sent for viral load testing.  
40 
Conclusion 
This study documented a high prevalence of depression among patients newly initiating 
ART and low retention in care at six months. However, the examined HIV care outcomes at six 
months were similar between those with and without depression. Further research is needed to 
understand the mechanisms through which depression may undermine different aspects of the 




CHAPTER V: THE IMPACT OF AN INTEGRATED DEPRESSION AND HIV 
TREATMENT PROGRAM ON MENTAL HEALTH AND HIV CARE OUTCOMES 




The burden of depression among people living with HIV in Malawi is high, ranging from 
1% to 19% 35,37,107,112, as in other sub-Saharan African countries.1  Depression is associated with 
poor HIV care engagement and ultimately increased HIV-related mortality and morbidity.1-6 The 
mechanisms through which depression undermines HIV care engagement are not fully clear. 
However, loss of interest, poor concentration, poor motivation, reduced self-efficacy, fatigue, 
hopelessness, and suicidality – key characteristics of depression – are all factors which can 
impair adherence and appointment attendance.2,4,46  Fortunately, depression treatment programs 
have been developed that have the potential to improve both HIV care and mental health 
outcomes, with a small but growing number of interventions adapted for low- and middle-
income countries.7-9,53,127,128 In places such as Malawi, where nearly 10% of the adult population 
is living with HIV129 and nearly a quarter of people living with HIV are lost to care in the first 
year of treatment26-28, incorporating depression screening and treatment into HIV care may be 
key to improving engagement in care across the HIV care continuum.  
There are limited resources for mental health care in Malawi, and a dearth of mental 
health infrastructure and specialists. Malawi treats mental healthcare as a specialized service, 
offered only by specialists in tertiary settings. There are only four psychiatrists and three 
functioning psychiatric hospitals in the country.130 In such settings where it is unlikely that the 
number of specialists and infrastructure could grow rapidly enough to meet the demands of the 
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population, task-shifting programs – i.e., models of care that shift specialized services to non-
specialists69 – are a popular and often cost-effective strategy for providing mental health 
services.71-73 Of the few depression treatment interventions developed for the sub-Saharan 
region, most employ a task-shifting model.53-59  
Two notable task-shifting interventions include algorithm-based care for depression58-60 
and the Friendship Bench behavioral activation and problem-solving therapy.56 Algorithm-based 
care is a resource-efficient, task-shifting model for prescribing antidepressant management in 
non-psychiatric settings. This model of care has demonstrated safety, feasibility, and 
acceptability when adapted for HIV care and delivered by general practice medical providers in 
Cameroon, Tanzania and Uganda.58-60 Developed over many years of formative research in 
Zimbabwe, the Friendship Bench is patient-centered counseling that teaches patients how to 
identify triggers and effectively manage stressful life events by learning or reactivating problem-
solving skills.56,61 These programs as well as others have proven efficacy in improving 
depression outcomes, though evidence on improvements in HIV care outcomes has been 
mixed.54,58-60,74,131,132 Further investment in understanding the feasibility of task-shifting program 
implementation and the effectiveness of these models of depression care is needed to meet the 
mental health care needs of people living with HIV.  
The Malawi Ministry of Health (MOH) has recognized the importance of addressing the 
burden of depression among people living with HIV as a means of improving engagement in 
HIV care. The MOH has also prioritized the integration of mental health services into other 
general health services and the development of mental health capacity of general providers.63-65 
Expanding the growing nidus of investment in mental health care programming and capacity 
development, the MOH implemented a pilot program integrating depression management into 
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HIV care at two public clinics in Lilongwe, Malawi, using both algorithm-guided depression 
treatment and adapted Friendship Bench therapy.95 Inspired by the key principles of 
implementation science, we use a multiple-baseline design to investigate the program’s impact 
on HIV care and depression outcomes.   
Methods 
Objectives 
The main objective of this study was to evaluate the program’s impact on retention, viral 
suppression, and depression remission among patients with elevated depressive symptoms at 
antiretroviral therapy (ART) initiation after six months in care. 
Study Design 
 This study employed a staggered multiple baseline (pre-post) design to evaluate a pilot 
program integrating depression screening and treatment into routine HIV primary care using 
existing staff at two public health clinics in Lilongwe, Malawi.111 Multiple baseline studies use a 
time-series design that can be used for studies with multiple sites in which each site intentionally 
receives the intervention at a different time point.111,133 This design can also provide evidence of 
causal relationships where randomization is not possible and provides stronger control for 
temporal trends.111,133 As such, the program rolled out in two phases, a screening-only “control” 
phase and an active “intervention” phase. The screening control phase launched at both clinics in 
April 2017. However, the launch of the intervention phase was staggered, launching at Clinic A 
in November 2017 and at Clinic B in April 2018 (Fig 5.1). Additional information on the study 
design is available in the published protocol paper.95  
Control Phase 
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During the control phase, providers screened patients for depression using the Patient 
Health Questionnaire-9 (PHQ-9). The PHQ-9, a nine-item screening questionnaire that assesses 
the presence and frequency of the nine Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition symptoms of major depression.80 It has been widely used in the region82,83,112 and 
was recently validated in Malawi among patients with diabetes.135 A total score of 5-9 is 
considered indicative of mild depressive symptoms and ≥10 is considered indicative of moderate 
to severe depressive symptoms.84  Patients who endorsed the last question of the PHQ-9, which 
asks about thoughts of being better off dead or hurting oneself, completed a suicide risk 
assessment protocol (SRAP) with the providers. The SRAP guided providers’ evaluation of 
whether such thoughts were passive or active. During the control phase, ART providers were re-
oriented to existing options for depression care within the Malawi primary care system.  These 
options theoretically include counseling and antidepressants, although in actuality counseling 
consists of informal counseling by ART providers and antidepressants are rarely prescribed.   For 
patients with suicidality, providers were trained to respond based on the level of severity, ranging 
from a brief safety assessment to immediate transport to the outpatient psychiatric department at 
the district hospital.  
 




 During the intervention phase, ART providers (nurses or clinicians) used PHQ-9 scores at 
ART initiation to triage patients by depressive severity. ART providers were trained to refer 
participants with mild depressive symptoms (PHQ-9 score 5-9) to clinic-based lay health 
workers or a project-employed counselor trained to provide an adapted problem-solving 
intervention called Friendship Bench therapy.54,56 These counselors provided patient-centered 
counseling that guided patients through recognizing problems, identifying their own solutions, 
implementing those solutions, and assessing the outcome.56,61 Patients referred to the Friendship 
Bench would ideally receive at least six counseling sessions. While these patients were 
encouraged to return weekly for Friendship Bench therapy, patients set their own appointments 
in line with the protocol’s patient-centered approach.  For participants with moderate to severe 
depressive symptoms (PHQ-9 score ≥10), ART providers were trained to prescribe 
antidepressants (fluoxetine or amitriptyline) with appropriate dosing and dose changes, using an 
algorithm-based care protocol.  Under this protocol, providers used PHQ-9 scores and drug side 
effects to guide antidepressant prescription, titrating the antidepressant dose by monitoring 
depressive symptoms and antidepressants side effects at each clinic visit58-60 (Table 5.1).  
Patients who started antidepressants were meant to be reevaluated monthly at their ART visits 
when they would be re-prescribed antidepressants for at least three months. Additional  
 
Table 5.1. Depression treatment overview, by study phase 
Score Depressive Severity Screening “Control” Phase  Active “Intervention” Phase 
0-4 No or minimal None None 
5-9 Mild No formal  
depression treatment – could 
include informal clinician 
counseling or, rarely, 
antidepressant prescription 
Friendship Bench 
10-27 Moderate to severe Antidepressants 
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information on the combined medication and counseling depression treatment program has 
previously been published.130  
Study Population 
  From April 2017 through November 2018, all non-pregnant adults newly initiating ART 
at the study sites were eligible to be included in the program evaluation. Pregnant women were 
excluded as they typically test for HIV at a specific antenatal care clinic and continue to receive 
ART as part of their antenatal care. This analysis is restricted to participants who completed 
depression screening and had elevated depressive symptoms (PHQ-9 score ≥ 5) at ART 
initiation. Participants were placed in the “control” or “intervention” groups based on the phase 
during which they initiated ART. 
 Control group: Includes participants with elevated depressive symptoms who initiated 
ART at either clinic during the screening “control” phase (e.g. at Clinic A between April 2017 
and November 2017 and at Clinic B between April 2017 and April 2018). 
 Intervention group: Includes participants with elevated depressive symptoms who 
initiated ART at either clinic after the launch of the treatment program during the active 
“intervention” phase (e.g. at Clinic A after November 2017 and at Clinic B after April 2018). 
Data Collection 
As an implementation science study, the primary objective was to assess the impact of an 
intervention that could readily (and rapidly) be adopted and integrated into routine care in the 
public sector setting.76,77 Just as the program made use of existing clinical staff and systems, the 
evaluation was intentionally designed to influence and disrupt the provision of care as little as 
possible by collecting only data that was already routinely captured during clinical care and 
using research staff only to consent patients and abstract data. Specifically, we did not conduct 
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baseline interviews or schedule six-month follow-up interviews, which would have limited 
enrollment and potentially brought participants back into care, biasing our primary outcome 
measure of HIV care engagement. Research assistants at the study sites approached potential 
participants during ART initiation to invite them to allow their clinical data to be used in the 
program evaluation. Research assistants abstracted routinely collected clinic data on depression 
and HIV care from consenting participants’ clinical records over a 13-month period, starting at 
ART initiation. Abstracted data included appointment dates, expected return dates, ART pills 
dispensed, PHQ-9 scores, and depression treatment provided. At ART initiation and each 
subsequent ART appointment, providers give patients a follow-up appointment date and a 
sufficient supply of ART. Generally, for the first six months of care, new ART patients receive a 
30-day supply of ART and a return appointment date in 30 days at each appointment. Most often, 
patients need to attend monthly ART refill appointments for their first six months of care in order 
to maintain their ART supply. Additionally, we obtained electronic medical record data from the 
clinical sites to ensure the quality and completeness of the abstracted data. 
Measures 
Exposures 
Adequate Friendship Bench therapy should consist of six sessions over the first six 
months in care and a standard course of antidepressants should consist of at least three 
consecutive months of antidepressant prescription with dosage adjustments as necessary. For 
analysis purposes, we have operationalized the intervention exposure as follows:  
Intent-to-treat: Intervention group participants were considered “exposed” to the 
intervention if they initiated ART during the intervention phase. Control group participants were 
considered “unexposed” to the intervention if they initiated ART during the control phase. 
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Treatment started: The intervention group included participants who either had: 1) mild 
depressive symptoms at ART initiation who started Friendship Bench therapy at ART initiation 
or 2) moderate to severe depressive symptoms who were prescribed antidepressants at ART 
initiation. The control group participants did not start Friendship Bench therapy or 
antidepressants at ART initiation.  
As treated: The intervention group included participants who attended at least their first 
follow-up appointment and either had: 1) mild depressive symptoms at ART initiation and at 
least two Friendship Bench therapy sessions over their first six months in care or 2) moderate to 
severe depressive symptoms at ART initiation and were prescribed at least two months of 
antidepressants over their first six months in care. The control group included participants who 
attended at least their first follow-up appointment, but did not have at least two Friendship Bench 
sessions or two months of antidepressant prescription over their first six months in care. Those 
participants who did not attend at least their first follow-up visit were excluded. While this 
definition was less stringent than the ideal course of treatment, this definition allowed for a more 
refined comparison of those who received early and consistent depression treatment compared to 
those who had not. 
Outcomes 
Retention was defined as never being more that 14 days late to an appointment through 
six months in care. Maintaining a consistent ART supply was defined as never more than five 
days without ART in the first six months, calculated from the cumulative days’ supply of ART 
dispensed at each appointment in the first six months and the time between appointments.  In 
alignment with the PEPFAR definition of “currently on treatment”91, participants were currently 
on ART six months after ART initiation if they attended an appointment and received a supply of 
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ART that would last through the six-month mark. Viral suppression was defined as a viral load 
of less than 1,000 copies/mL drawn after at least five and a half months (166 days) in care. 
Depression remission was defined as a PHQ-9 score of less than five taken after at least five and 
a half months (166 days) in care, to allow for completion of the acute phase of treatment and 
maintenance of that response.96  Additionally, we examined the proportion of scheduled HIV 
appointments attended within one week during the first six months of care and the ART pill 
possession ratio, the proportion of the first six months (183 days) since ART initiation with ART 
in hand, calculated from cumulative pills dispensed at each ART appointment through six 
months. 
Covariates 
  Due to the implementation science nature of this study, we only abstracted routinely 
collected clinical data. Measured covariates included the healthcare facility where patients 
received ART (Clinic A or B), months since program launch at ART initiation, gender, age, 
baseline depressive severity at ART initiation (mild or moderate to severe), and baseline 
presence of suicidal thoughts at ART initiation. Presence of suicidal thoughts was defined as any 
endorsement of the ninth question of the PHQ-9: “During the past two weeks, how many days 
have you been bothered by thoughts that you would be better off dead or of hurting yourself in 
some way?”  
Data Analysis 
 The main analysis followed an “intent-to-treat” approach, classifying participants 
according to screening “control”  vs. active “intervention” phase (unexposed vs. exposed to the 
program) without regard to actual treatment received. Although patients identified with elevated 
depressive symptoms late in the control phase could theoretically have received depression care 
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from providers during the intervention phase during their first six months of care, in practical 
terms, depression treatment was only provided to patients newly entering care. Furthermore, we 
monitored crossover between groups. We first completed unadjusted, tabular comparisons of 
HIV care and depression outcomes in the intervention group relative to the control group. We 
then used log-binomial models to estimate adjusted risk ratios comparing the probability of the 
primary outcome, retention with viral suppression, as well as the probability of other secondary 
HIV care outcomes in the intervention group compared to the control group.  Since the 
evaluation employed a staggered multiple baseline design, with the intervention launching at 
different dates at the two clinics, all models were adjusted for clinic and months since program 
launch to allow for the assessment of and potential correction for any secular trend in outcomes 
(“confounding by history”). While the study design should have produced comparable control 
and intervention groups, we did additionally consider controlling for measured covariates. To 
separately evaluate the impact of the Friendship Bench and the antidepressant treatment, we then 
stratified the primary analysis by depressive severity at baseline (mild or moderate to severe 
depressive symptoms). Other secondary analyses used a “treatment started” approach, comparing 
those who actually started Friendship Bench therapy or antidepressants to those that did not in 
both phases and then an “as treated” approach, comparing those who received at least two 
Friendship Bench therapy sessions or two months of antidepressants to patients who did not in 
both phases, restricted to only those who attended at least their first follow-up visit. 
 Outcome data for those who transferred or died in the first six months of care were 
treated as missing. To address missing outcome data, we used multiple imputation by chained 
equations (MICE) to fill missing values using logistic regression imputation methods.97 We 
imputed values based on phase, healthcare facility, months since program launch at ART 
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initiation, age, sex, baseline depressive severity at ART initiation, and baseline presence of 
suicidality at ART initiation. We generated 18 imputed datasets to ensure the number of imputed 
datasets was at least as large as the percentage of incomplete information for the main outcome, 
“retention with viral suppression.”113 To verify that this was sufficient, we confirmed that the 
number of imputed datasets was also larger than the parameter-specific fraction of missing 
information for all parameters included in the final model.114  
 All analyses were performed using STATA IC 14.   
Ethical Review 
  The National Health Sciences Research Committee of Malawi (NHSRC) and the 
Biomedical Institutional Review Board (IRB) of the University of North Carolina at Chapel Hill 
approved the study protocol.  All participants gave written informed consent to allow the 
abstraction of their clinical data. The evaluation only used de-identified clinic data to ensure the 
protection of participants’ identities and confidentiality. Patients with depression received 
depression care regardless of whether or not they provided consent for their data to be abstracted.   
Results 
Depression Screening 
  Over the course of the program, 2414 patients newly initiated ART (Fig 5.2). Of these  
new initiators, 2067 (86%) consented to allow their data to be abstracted to evaluate the program. 
Nearly all of those who consented (96%) were screened with the PHQ-9 appropriately. Among 
those who completed the PHQ-9 screening, the prevalence of mild depressive symptoms (PHQ-9 
score 5-9) was 19% and the prevalence of moderate to severe depressive symptoms (PHQ-9 
score ≥ 10) was 6%. Only those participants with elevated depressive symptoms (PHQ-9 score ≥ 




Figure 5.2. Evaluation enrollment
 
Participant Characteristics 
  Of the 501 consenting participants with elevated depressive symptoms, the control group 
consisted of the 290 who initiated ART during the control phase and the intervention group 
consisted of the 211 who initiated during the intervention phase (Table 5.2). As the program 
launched later at Clinic B, a larger proportion (75%) of the intervention group were from Clinic 
A. Otherwise, the two groups appear very similar. About 43% of participants were male. The 
average age of participants was 33.8 years. Nearly all participants were classified as 
asymptomatic (Stage I) for HIV at ART initiation, according to the World Health Organization’s 
(WHO) HIV clinical stages for HIV surveillance 88. At ART initiation, 74% of participants had 
mild depressive symptoms, only around 1% of participants had severe depressive symptoms and 
21% of participants reported suicidality.   
Depression Treatment Exposure 
Initiating Depression Treatment 
Among the control group, 89% of participants with mild depressive symptoms and 80% 
participants with moderate to severe depressive symptoms received some additional counseling 
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by ART clinicians (“standard depression care” during the control phase) (Table 5.3). During this 
phase, only 18% (n=14) of those with moderate to severe depressive symptoms started 
amitriptyline during the control phase and most (n=11) started at a subtherapeutic dose of 25 mg.  
 
Table 5.2 Participant characteristics (N=501)  
n(%) or mean (sd) Overall Control Group  Intervention Group 
Overall 501 290 211 
Clinic 
   
   Clinic A 276 (55%) 116 (40%) 160 (76%) 
   Clinic B 225 (45%) 174 (60%) 51 (24%) 
Sex 
   
   Male 214 (43%) 125 (43%) 89 (42%) 
   Female 287 (57%) 165 (57%) 122 (58%) 
Age 33.8 (9.5) 33.6 (10.0) 34.0 (8.7) 
WHO Disease Stage 
   
   I 498 (99%) 288 (99%) 210 (>99%) 
   II-IV 3 (1%) 2 (1%) 1 (<1%) 
Baseline Depressive Severity 
   
   Mild (PHQ-9: 5-9)  370 (74%) 214 (74%) 156 (74%) 
   Moderate (PHQ-9: 10-19)  126 (25%) 71 (24%) 55 (26%) 
   Severe (PHQ-9: 20-27)  5 (1%) 5 (2%) 0 (0%) 
Baseline Suicidality 
   
   No thoughts 397 (79%) 228 (79%) 169 (80%) 
   Passive thoughts 53 (11%) 33 (11%) 20 (9%) 
   Active thoughts 46 (9%) 27 (9%) 19 (9%) 
   Not assessed with SRAP 5 (1%) 2 (1%) 3 (1%) 
Notes: SRAP=Suicide Risk Assessment Protocol. PHQ-9=Patient Health Questoinnaire-9. WHO=World Health 
Organization. 
 
Most of the intervention group started the appropriate treatment as defined by the intervention 
protocol during the intervention phase. During this phase, 86% of participants with mild 
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depressive symptoms started Friendship Bench therapy and nearly all (96%) participants with 
moderate to severe depressive symptoms started antidepressants. All of the participants with 
moderate to severe depressive symptoms who started antidepressants at ART initiation started at 
a minimal effective dose (operationally defined as a daily oral dose of either 20 mg of fluoxetine 
or 50 mg of amitriptyline). 
 
Table 5.3. Depression treatment initiation 
 N (%) Control Group  Intervention Group 
Mild depressive symptoms (PHQ-9: 5-9) 214 (100%) 156 (100%) 
  Counseling by clinician 191 (89%) 15 (10%) 
  Friendship Bench therapy - 134 (86%) 
  Antidepressant*  2 (1%) 2 (1%) 
  None** 21 (10%) 5 (3%) 
   
Moderate to severe depressive symptoms (PHQ-9:  ≥10) 76 (100%) 55 (100%) 
  Counseling by clinician 60 (79%) 2 (4%) 
  Friendship Bench therapy - 0 (0%) 
  Antidepressant*** 14 (18%) 53 (96%) 
  None 2 (3%) 0 (0%) 
Notes: *Includes those who received both antidepressants and the Friendship Bench (n=2). **Those with missing 
baseline treatment plan (n=4) are treated as none. ***Includes those who received both antidepressants and 
counseling by clinician (n=8) or both antidepressants and the Friendship Bench (n=4). 
 
Provision of Ongoing Depression Treatment 
Few patients in the intervention group continued to receive ongoing depression treatment 
during the intervention phase after ART initiation. Only 42% of participants referred to the 
Friendship Bench attended three or more therapy sessions (Table 5.4). Of those who were 
prescribed antidepressants, less than a third of participants (n=17) received three or more months 
of antidepressant prescription. Only six of those participants received at least three consecutive 
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months of the same antidepressant.  Inadequate sustained treatment was in part due to poor 
appointment attendance, medication stock-outs, and clinicians’ failure to identify patients with 
elevated depressive symptoms at follow-up ART appointments. However, it did not appear that 
there was much crossover between groups. None of the control participants ever started 
Friendship Bench therapy and very few started antidepressants at ART initiation (n=16) or at a 
follow-up visit (n=6).  
 
Table 5.4. Depression treatment over time 
   Control Group  Intervention Group  
Of those directed to Friendship Bench:* 
 -  140 (100%)  
Number of sessions attended 




 -  60 (43%)  
2 
 -  21 (15%)  
≥3 
 -  59 (42%)  
Of those prescribed antidepressants:** 
 16 (100%)  55 (100%)  
Number of months antidepressants provided 




 13 (81%)  23 (42%)  
2 
 2 (13%)  15 (27%)  
≥3 
 1 (6%)  17 (31%)  
Notes: *Includes those who were referred to the Friendship Bench and those who were both prescribed 
antidepressants and referred to the Friendship Bench. **Includes those who were prescribed antidepressants and 
those who were both prescribed antidepressants and were referred to the Friendship Bench.  
 
Program Impact  
Most HIV and mental health outcomes did not appear to differ between groups. (Table 
5.5). Retention in both arms was poor; approximately a third of participants in both groups 
remained in care through six months. Just over half of the control group and just under half of 
the intervention group were currently on ART at six months. Close to 40% of participants in both 
the control and intervention phases maintained a consistent ART supply (never more than 5 days 
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without ART) through six months. Many participants had missing data for viral suppression and 
depression remission after 5.5 months; only 36% (n=181) of participants had viral load draw 
after 5.5 months and 26% of participants (n=132) had a measured PHQ-9 score. Among those 
with a measured viral load or PHQ-9 score after 5.5 months, respectively, viral suppression and 
depression remission were high (>91%) in both groups. Findings were similar when stratified by 
baseline depressive severity (mild or moderate to severe) and when using a “treatment started” 
and an “as treated” approach (Appendix Tables 1-4).  
 
Table 5.5. Program impact on HIV and depression outcomes 
 n (%) or mean (sd) Control Intervention 
 Retention: never >14 days through 6 months 91/266 (34%) 66/186 (35%) 
 HIV appointment attendance: average proportion of scheduled  
 appointments attended through 6 months (Range: 0-1) 0.57 (0.39) 0.59 (0.38) 
   Currently on ART: attended appointment prior to 6 months 
   with next scheduled appointment after 6 months 138/266 (52%) 87/186 (47%) 
   Consistent ART:  never >5 days without ART through 6 months 112/266 (42%) 73/186 (39%) 
   ART pill possession: average proportion of days with ART 
   through 6 months (Range: 0.16-1) 0.69 (0.35) 0.67 (0.37) 
   Viral suppression: VL < 1,000 copies/mL after 5.5 months, 
   among those with a viral load 108/115 (94%) 60/66 (91%) 
   Depression remission: PHQ-9 score < 5 after 5.5 months,  
   among those with a PHQ-9 score 87/93 (94%) 37/38 (97%) 
Notes: This table does not include data on individuals who transferred within the first 6 months of care: Control 
Phase n=24; Intervention Phase n=25. Denominators vary due to viral loads not being drawn, the PHQ-9 not being 
administered, not having or attending a scheduled appointment around 6 months. ART=antiretroviral therapy. PHQ-
9=Patient Health Questionnaire-9. VL=viral load.  
 
To assess potential bias due to missing data from transferring or attending care without 
getting a 6-month viral load or PHQ-9 assessment, we compared baseline information between 
those with and without missing data. While a larger proportion of transfers were from Clinic A, 
missing data did not appear to be associated with any other measured baseline characteristics 
(Appendix Tables 5-7).  
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The final adjusted model controlled for clinic, months since program launch at ART 
initiation, sex and baseline depressive severity. Both age and baseline presence of suicidality 
introduced model instability. As age did not appear to be associated with any of the outcomes or 
program exposure, we ultimately removed it from the model. We only retained baseline 
depressive severity in the final adjustment set as baseline presence of suicidality was highly 
correlated with baseline depressive severity.   
In the adjusted “intent-to-treat” analysis, program exposure did not demonstrably affect 
the primary outcome, retention with viral suppression at six months (Table 5.6). While no 
difference was evident for most of the secondary outcomes, the probability of currently being on 
ART at six months and the ART pill possession ratio was significantly lower among the 
intervention group than among the control group [RR 0.6(95%CI: 0.4-0.9) and Mean Difference 
-0.1(95%CI: -0.3-0), respectively]. Correction for missing data with multiple imputation did not 
have a significant impact on any of the outcomes. When stratified by baseline severity, only the 
probability of being on ART at six months was significantly lower during the intervention phase  
 
Table 5.6. Effect of intervention on HIV care and depression outcomes 
 Outcome Adjusted* Imputation** 
 RR or Mean Difference (95%CI) 
 Retention: never >14 days through 6 months 1.1 (0.6-1.9) 1.1 (0.6-1.9) 
   HIV appointment attendance: average proportion of scheduled  
   appointments attended through 6 months 0.0 (-0.1-0.2) 0.0 (-0.1-0.1) 
   Currently on ART: attended appointment prior to 6 months 
   with next scheduled appointment after 6 months 
0.6 (0.4-0.9) 0.6 (0.4-0.9) 
   Consistent ART:  never >5 days without ART through 6 months 0.8 (0.5-1.2) 0.8 (0.5-1.3) 
   ART pill possession: average proportion of days with ART 
   through 6 months (Range: 0.16-1) -0.1 (-0.3-0.0) -0.1 (-0.4-0.1) 
Notes: *Adjusted for clinic, months since program launch (quadratic term), sex, and baseline depressive severity. 
**Further corrected for missing data via multiple imputation. ART=antiretroviral therapy. 
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than during the control phase [RR 0.33(95%CI: 0.13-0.83)] among those with moderate to severe 
depressive symptoms at baseline (Appendix Table 8).  The “treatment started” and “as treated” 
approaches generally showed similar results (Appendix Tables 9-10). 
Discussion 
We investigated the impact of a program integrating depression management into HIV 
care initiation on six-month HIV care and depression outcomes. Clinic staff screened nearly all 
patients for depression, documenting the prevalence of mild and moderate to severe depressive 
symptoms among people newly initiating ART. During the intervention phase of the program, 
they successfully started the majority of the intervention group on the appropriate depression 
treatment. However, providing ongoing treatment proved more challenging, and few patients 
received a standard course of antidepressants or attended a sufficient number of Friendship 
Bench therapy sessions. Retention was very low in both the intervention and control groups. 
Nearly all participants who did remain in care and had a six-month viral load drawn and PHQ-9 
assessment achieved viral suppression and depression remission.  However, the evaluation did 
not yield evidence that the integrated depression treatment program improved six-month HIV 
care or depression outcomes among the intervention group compared to the control group. 
The successful integration of depression screening allowed this evaluation to document 
the prevalence of depression among people newly initiating ART. A growing body of research is 
beginning to establish the magnitude of mental health disorders in Malawi. In Malawian primary 
care settings, a third of all patients have a common mental disorder, most commonly 
depression.34  However, few studies have estimated the prevalence of depression among the 
general adult population of people living with HIV. We found that around a quarter of people 
newly initiating ART at the study sites had mild to severe depressive symptoms. This finding is 
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only slightly higher than estimates from various subpopulations (adolescents, pregnant women, 
adults receiving HIV care) of people living with HIV in Malawi35,37,112 and supports other sub-
Saharan regional estimates of depression prevalence.1 Such evidence indicates a clear need for 
depression treatment among people living with HIV. 
The integration of depression screening and treatment initiation at the time of ART 
initiation appeared feasible. During ART initiation, nearly all of the 2067 participants who 
consented to participate in the study were successfully screened for depression. Further, nearly 
all intervention participants started the treatment appropriate for their depressive severity at ART 
initiation. Factors that may have contributed to this success include the effective utilization of 
existing ART initiation processes and the creation of a collaborative training environment 130. 
For example, after careful study of patient flow, we designed the initial PHQ-9 screening to be 
shared by the HTC counselors and the ART providers, distributing the additional work and time 
burden. We also ensured that every HIV provider received training in how to administer and 
interpret the PHQ-9, provide depression treatment, and manage depression symptoms over time 
– creating opportunities for iterative learning and ongoing support.130 Another task-shifting study 
in Uganda found that both depression screening by lay workers and antidepressant treatment 
initiation by ART provider were feasible, a success the researchers attributed to ongoing training 
and appropriate mentorship.60 As such, using non-psychiatric specialists to screen and triage 
cases of depressions appears possible in this sub-Saharan setting.  
While effective integration into existing processes was key to the success of depression 
screening and treatment initiation, the aspects of existing infrastructure and supply management 
that the program was unable to effectively utilize hampered the provision of sustained depression 
treatment.  Providers at the study sites typically rely on an electronic medical record (EMR) 
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system to provide ART, which did not incorporate PHQ-9 screening or depression treatment and 
thus did not alert providers to re-assess depressed patients returning for care. Despite developing 
a system of marking patients’ health passports so that those needing depression treatment re-
evaluation could be identified, providers struggled to re-identify depressed patients returning for 
ART care.130 Very few studies on task-shifting models of care in the region have relied on 
existing staff (as opposed to study-employed staff) or assessed the provision of depression 
treatment over time.  For example, the study evaluating different task-shifting strategies for 
depression treatment in Uganda only reported on depression treatment initiation60, making 
comparisons challenging.  Other implementation science studies will need to track and assess the 
provision of treatment over time.  
Antidepressant stock-outs were also common and problematic. While the Malawi 
Ministry of Health has committed to making antidepressants freely available at health center 
pharmacies 65, ensuring their availability was complicated and required substantial coordination, 
often beyond the scope of work of the health center pharmacist. Other countries such as 
Mozambique with similar policies on the provision of antidepressants have also experienced 
challenges stocking these medications at the district or clinic level.136 Another task-shifting 
depression program in Tanzania also experienced antidepressant stock-outs.58  Greater 
engagement and investment of health sector stakeholders involved in the procurement, supply 
and distribution of drugs such as Malawi’s Central Medical Stores is required to ensure 
antidepressant stocks are maintained to ensure the success and safety of depression treatment 
programs. 
The clinics also found it challenging to provide proper Friendship Bench therapy, in part 
due to community health care workers’ availability and in part due to patients’ ability to return to 
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the clinic for therapy sessions, in light of financial, time, and transport barriers119. As the 
community health workers already had a very high workload and often traveled off-site to run 
various Ministry of Health initiatives, the one program-employed counselor at each site 
ultimately provided the majority of the therapy sessions. Community health workers are often 
already overloaded with work and are at risk of becoming additionally overburdened when 
drawn into task-sharing models of care137,138, as was potentially the case at the study sites. 
Furthermore, while the original Friendship Bench protocol called for six weeks of weekly 
therapy sessions56, patients were reluctant to make additional trips to the clinic primarily due to 
time and transportation barriers. This resulted in scheduling Friendship Bench sessions to 
coincide with the patients’ monthly ART refill appointments. While attending weekly sessions 
appeared acceptable in the original Friendship Bench program56, it is difficult to tell from other 
adaptations as they may have incentivized attending sessions with reimbursement.139 These 
findings highlight the importance of implementation science research to establish the real-world 
feasibility of task-shifting depression care for people living with HIV.  
As implemented, the program did not appear to improve HIV care or depression 
outcomes, as few patients received depression treatment as intended. Studies in the region have 
found that similar programs, albeit with higher fidelity to their treatment protocols, have been 
effective at treating depression.74,131 In our study, nearly all participants achieved depression 
remission, regardless of depression treatment. As many of these other evaluations of depression 
treatment programs were quite small or did not include control arms74,131, it is possible that 
depressive symptoms could have improved in the absence of depression treatment. However, it 
should be noted that we could have overestimated six-month depression remission if patients 
who did not remain in care were more likely to have persistent depressive symptoms.  In regards 
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to the program’s impact on HIV outcomes, the literature on linking depression treatment to 
improvements across the HIV care cascade is mixed.7-15,53,139,140 A recent meta-analysis of 
depression treatment interventions for people living with HIV in sub-Saharan Africa also did not 
find that interventions improve viral suppression, though they did conclude that the programs 
with an ART adherence component had the greatest impact on HIV outcomes131. As it was 
impossible for the program to have a pure control group in which patients were denied 
depression treatment, it is possible that providers discussed the depression screening results with 
participants or provided brief additional ART adherence counseling. While even unstructured 
additional patient attention has the potential to impact engagement in care, it is no substitute for 
evidence-based depression treatment and adherence counseling interventions. Further research is 
needed to understand the factors that influenced adherence to the program protocol and to 
identify the more effective ways to implement depression treatment programs that will improve 
depression and HIV care outcomes.  
 Retention in care was remarkably low in both of the study phases; only a quarter of 
patients achieved retention and viral suppression at six months. Aligned with PEPFAR’s less-
stringent definition of being in care at six months (our “currently on ART” measure)91, only half 
of patients were retained at six months. These estimates are much lower than national 12-month 
estimates from 2018, which found that 65% of adults who initiated ART were still in care at 12 
months.141 However, as our entire study population had elevated depressive symptoms, it 
possible that depression is responsible for this difference in retention. The program did not 
appear to improve HIV care engagement, even when using the “treatment started” or “as treated” 
approach, and in the main analysis the intervention group was significantly less likely to 
currently be on ART at six months than the control group. It is possible that this population faced 
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other barriers to care that were more relevant and difficult to overcome, such as human resource 
and institutional challenges, distance to the clinic, lack of support, and stigma and fear of HIV 
status disclosure.24,29-31 Nonetheless, there is a distinct need for urgent action to improve early 
retention in care for people living with HIV and depression.   
Limitations 
The results should be considered in light of several limitations. Although the study’s 
design was not guided by a formal implementation science framework, the study was designed in 
congruence with the key principles of implementation science, using methods that would 
promote the systematic uptake of evidence-based practices (e.g. the Friendship Bench and 
algorithm-based care) into routine care.142,143  In line with the implementation science-inspired 
design of the study and our efforts not to unduly influence the provision of or engagement in 
care, all of the measures were drawn from routinely collected medical chart data. As we did not 
conduct baseline interviews or schedule six-month follow-up interviews, we captured limited 
information on potential confounders. A large proportion of patients did not have six-month viral 
loads or PHQ-9 scores due to either dropout or provider failure to refer patients for viral load 
testing or screen patients appropriately.  Still, the multiple baseline design should have protected 
against confounding from unmeasured confounders by producing balanced characteristics across 
phases, as evident from similar characteristics of intervention and control groups seen in Table 
5.2. Additionally, the program struggled to establish a sense of ownership among providers, 
develop capacity to manage depression treatment over time, and ensure the availability of 
antidepressants, which may have impacted providers’ adherence to the depression treatment 
protocol.130 As an extension of this challenge, ART providers administered the six-month PHQ-
9, so part of the observed reduction in PHQ-9 scores could be due to less careful administration.  
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All of the HIV engagement measures may have been influenced by participants who 
sought care at another facility without formally transferring their records. These “silent transfers” 
would have been misclassified as being out of care. However, as the rate of silent transfers 
should not have varied between groups, this potential measurement error should not have 
introduced bias into the analyses. 
Conclusion 
This experience demonstrated that while it is feasible to integrate depression screening 
and treatment initiation into ART initiation, providing ongoing depression treatment over time is 
challenging; very few patients received ongoing depression treatment for many of the reasons 
discussed above. In this setting, it is clear that in order for such a program to be successful, 
additional resources are needed to support ongoing capacity building, ensure the availability of 
Friendship Bench counselors and antidepressants, encourage patient engagement in the full-
course of treatment, and further integrate into the electronic medical records system. 
Additionally, further research is needed to explore the other factors that potentially govern both 
the implementation of and engagement with such a program. While the evaluation did not yield 
evidence that the program improved HIV care or depression outcomes in a real-world clinic 
setting, depression treatment in sub-Saharan Africa is efficacious for improving mental health 
and engagement in HIV care in more controlled research environments.74 Further, this program 
targeted patients newly initiating ART, often at the highest risk for loss to care. Further research 
could explore whether other patient populations may benefit from depression treatment, such as 
those returning for care with elevated depressive symptoms or whether depression treatment for 
people living with HIV may be more effective if it includes a specific component supporting 
ART adherence or HIV care engagement.  Moving the field of mental health care in low- and 
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middle-income countries forward, similar implementation science studies will be increasingly 
important as we strive to understand and test the best ways to implement evidence-based 






CHAPTER VI: MIXED-METHODS PROCESS EVALUATION OF THE 
IMPLEMENTATION OF A PILOT DEPRESSION TREATMENT PROGRAM 
 
Introduction 
The burden of depression is high among people living with HIV, particularly in sub-
Saharan Africa (SSA).1 Beyond the morbidity produced in its own right, depression hinders 
engagement in HIV care and antiretroviral therapy (ART) adherence, which ultimately predict 
HIV clinical morbidity and mortality.1-6 Despite the deleterious impact of untreated depression 
among people living with HIV, investment in mental healthcare is lacking across the globe and 
especially in resource-limited settings such as in SSA.144 Fortunately, interventions to address the 
burden of depression among people living with HIV are being developed50,51, with several 
directed specifically for SSA or other settings with limited psychiatric infrastructure and human 
resources.52-58 
To address the burden of depression among people living with HIV, the Malawi Ministry 
of Health (MOH) implemented a pilot task-shifting program that integrated depression 
management into ART care initiation at two clinics in Lilongwe, Malawi.95,130 As part of this 
program, existing clinic-based staff provided two evidence-based depression treatment 
interventions, including measurement-based care (MBC) antidepressant prescription58-60 and the 
Friendship Bench problem-solving therapy.56,61 Despite the proven safety and efficacy of these 
treatment models, the initial program evaluation found that the treatment program did not 
improve retention, viral suppression or depression remission.89  
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The ultimate impact of health innovations depends not only on the effectiveness of the 
intervention, but also on its reach in the population and the extent to which interventions are 
properly adopted, implemented and maintained over time.145 In this manuscript, we first describe 
how the program was designed. We then present a mixed-methods process evaluation 
investigating the extent to which our implementation strategy was delivered with fidelity, 
deemed acceptable by providers and patients, and sustained after the conclusion of the program 
evaluation. This mixed-method investigation allows us to contextualize our previous findings, 
share insights from the implementation experience, and comment on the feasibility of our 
implementation strategy. 
Program Overview 
The pilot program integrated depression screening at treatment into ART initiation at 
two, semi-urban, primary level health facilities in Lilongwe, Malawi. These public facilities 
provide services free of charge and encompass an ART clinic, similar to a department. Only one 
facility employs a psychiatric nurse who does not regularly offer specialized psychiatric services. 
Private mental health care specialists irregularly offer mental health clinic days at the facilities. 
Otherwise, patients can be referred to the psychiatric department at the district hospital. Further 
details on the health facilities available in previous publications.130 
HIV testing and counseling (HTC) counselors and ART providers were trained to screen 
patients newly initiating ART for depression using the Patient Health Questionnaire-9 (PHQ-9), 
a nine-item depression screening questionnaire that has been widely used in the 
region.82,83,112,134,135 HTC counselors were to screen patients who tested positive for HIV with the 
first two questions of the PHQ-9 [called the Patient Health Questionnaire-2 (PHQ-2)] that screen 
for depressed mood and anhedonia. ART providers were to complete the remaining seven 
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questions of the PHQ-9 with any patients who reported either of the symptoms captured by the 
PHQ-2. ART providers were instructed on how to provide depression treatment to patients based 
on their depressive severity (Figure 6.1).  
Figure 6.1. Depression management during the intervention phase  
 
ART providers were trained to treat moderate to severe cases of depression (PHQ-9 score 
≥10) with antidepressants (amitriptyline or fluoxetine) using measurement-based care (MBC) 
(Figure 6.1). MBC is a resource-efficient, task-sharing model for prescribing antidepressant 
management in non-psychiatric settings that has demonstrated safety, feasibility, and 
acceptability when adapted for HIV care and delivered by non-specialists in Cameroon, Tanzania 
and Uganda.58-60 The pharmacies at the health facilities were instructed to stock amitriptyline and 
fluoxetine, two antidepressants that are considered “essential medicines” under Malawi’s 
Essential Health Package and are meant to be freely available for patients at health facilities.63,64 
ART providers were instructed to discuss the available antidepressants with the patient and 
jointly decide on the best option for the patient. When patients returned for ART care, ART 
providers were then meant to reassess patients’ depressive symptoms, evaluate their response to 
the depression treatment and prescribe antidepressants as necessary. The study staff hung posters 
in the ART clinic rooms that provided an overview of the MBC protocol and detailed how to use 
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PHQ-9 scores and side-effect tolerability to guide changes in dosage or type of antidepressant. A 
standard course of antidepressants should consist of at least three consecutive months of 
antidepressant prescription with dosage adjustments as necessary.  
ART providers were trained to refer cases of mild depression (PHQ-9 score 5-9) to clinic-
based community health workers [called Health Surveillance Assistants (HSAs)] who were 
trained to provide Friendship Bench problem-solving therapy (Figure 6.1) Friendship Bench 
therapy is an adapted form of problem-solving therapy or patient-centered counseling that was 
developed in Zimbabwe and teaches patients how to identify triggers and effectively manage 
stressful life events by learning or reactivating problem solving skills.56,61 Patients referred to the 
Friendship Bench were to receive at least six counseling sessions, with adequate treatment 
comprising at least six sessions within the first six months. While Friendship Bench counselors 
were meant to encourage patients to return weekly for Friendship Bench therapy, patients were 
asked to set their own appointments in line with the protocol’s patient-centered approach. The 
study also employed one Friendship Bench counselor at each site, to provide back-up support the 
HSAs trained in the Friendship Bench protocol. Additionally, the study built covered shelters at 
both sites as a dedicated space for the Friendship Bench therapy.  
Throughout the program implementation, the study coordinator held bi-monthly meetings 
at each site to support clinic staff and leadership deliver the program. However, the study staff 
were otherwise not meant to assist in the provision of daily clinical care and were only meant to 
consent patients and abstract their clinical data. Prior to the conclusion of the program 
evaluation, the study coordinator worked with the health facility staff and leadership to transition 
ownership of the program entirely to the health facilities. As such, the HIV providers were to 
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continue screening and treating patients as before after the study ended. Previous publications 




After the launch of the intervention, all non-pregnant adults newly initiating ART were 
exposed to the depression screening and treatment program and eligible to participate in the 
program evaluation. Between April 2017 and November 2018, study staff approached potential 
participants during the ART initiation process to invite them to allow their clinical data to be 
used in the program evaluation. Study staff abstracted sociodemographic information as well as 
data on depression and HIV care from consenting participants’ clinical records over a 13-month 
period, starting at ART initiation. Again, further details on enrollment in the program evaluation, 
clinical data abstraction and the measures captured have been previously published.89,95 Only 
participants with elevated depressive symptoms (PHQ-9 ≥ 5) at ART initiation are included in 
this mixed-methods process evaluation. All analyses were performed using STATA IC 14. 
Qualitative Data 
In-depth interviews were conducted over after the launch of the intervention between 
June and December 2018 with the following objectives: 1) explore providers’ and patients’ 
attitudes towards and experiences with the depression treatment intervention; 2) understand 
barriers and facilitators to integrating depression treatment into HIV care; and 3) prepare for the 
long-term sustainability of the program after the conclusion of the program evaluation. The 
qualitative interviews were conducted with a convenience sample of patients with depression at 
ART initiation who were referred to the Friendship Bench or prescribed antidepressants, ART 
providers, Friendship Bench counselors, and clinic leadership. Prior to data collection, study staff 
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met with the administrators at both health centers and drew up a list of staff. The study 
coordinator or interviewer approached staff and leadership at the clinic to schedule interviews. 
The study staff identified patients returning for ART services and invited these patients to 
participate. An effort was made to interview a range of men and women as prior research has 
shown attitudes towards depression and the provision mental health care may vary by the gender 
of both providers and patients.85-87  The research team developed semi-structured interview 
guides based on the study objectives. Interviews were conducted in either Chichewa (the local 
language) or English, based on participants’ preference, by a Malawian woman with a 
background in qualitative research and HIV care services. All interviews were held at the 
respective health facility in a private location. The interviews were audio-recorded, translated 
and transcribed to English. The research team reviewed transcripts as they became available, and 
provided feedback to the interviewer throughout the data collection process to ensure quality.  
After reading each of the transcripts, the author (MS) drafted a thematic codebook that 
would address the study objectives and capture emerging themes evident from her initial review 
of the transcripts 98,99. As such, many codes were developed a priori, given that the interview 
questions were linked to the program implementation, while others were developed a posteriori. 
MS then met with research team members who had simultaneously been reviewing the 
transcripts to review and finalize the codebook. Two coders coded a subset of the same 
transcripts from each round to ensure consistency in their use of the codes using NVivo (Version 
12). Coding was treated as an iterative process and the coders met several times throughout to 
discuss the addition, definition, and appropriate use of the codes that emerged from the data. 
Additionally, the coders wrote memos for the individual transcripts and on emerging themes. 
Upon completion of coding, MS executed queries in NVivo and both she and the second coder 
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(CM) reviewed coded data related to the key aspects of program implementation, depression 
treatment initiation, depression treatment over time, acceptability, and sustainability. While 
synthesizing these findings, MS met with the study team to ensure accurate interpretation of the 
interviews. 
Implementation outcomes 
We defined these implementation outcomes in line with Proctor and colleagues’ 
conceptualization of implementation science research outcomes and Caroll and colleagues’ 
framework for implementation fidelity.146,147 Fidelity is the degree to which this program was 
implemented as intended or adherence to the program protocol. Acceptability is the perception 
among stakeholders and consumers, in this case health facility staff, leadership and patients, that 
the program is agreeable or satisfactory based on their knowledge, experience, and comfort with 
the program’s content and complexity. Sustainability is defined as the extent to which the 
program is maintained within the health facilities’ ongoing operations after the conclusion of the 
program evaluation. We assess each of these outcomes in the following manner:  
Fidelity 
We examined adherence to the program protocol in terms of content, coverage, 
frequency, and duration147 by using clinical data to determine whether patients initiated the 
correct depression treatment (content) based on their depressive severity (coverage) and whether 
these patients continued to attend Friendship Bench therapy sessions or receive antidepressants 
(frequency) over their first six months in care (duration). Data from the qualitative interviews 
explain and contextualize the quantitative fidelity measures.  
Acceptability  
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We used data from the qualitative interviews to explore participants’ views towards 
delivering the program and its impact on patient outcomes. We specifically considered 
providers’ comfort with the depression treatment options, their opinions about the complexity of 
the program, and various structural impediments to program delivery. Additionally, patients’ and 
providers’ experiences with the program’s effect on patient health outcomes were also reviewed. 
Sustainability 
We examined screening rates soon after the study stopped enrolling participants in the 
program evaluation (from February to May 2019) and then again in December 2019. We also 
used discussions with clinic staff and leadership about maintaining the program in the future to 
help understand these findings.  
Ethical Considerations 
We sought and obtained approval from both the Malawi MOH’s National Health Science 
Research Committee (NHSRC) institutional review board (IRB) and the Biomedical IRB of the 
University of North Carolina at Chapel Hill. All participants who agreed to participate in the 
study provided informed consent. Qualitative study participants were given a travel 
reimbursement equivalent of and 10USD (7,000MK). The study team collected no identifying 
information and maintained unlinked consent forms, abstracted clinical data, and transcripts. 
Results 
We first describe the characteristics of the study participants and then assess fidelity, 
acceptability and sustainability. Fidelity is examined in regards to depression treatment initiation 
and engagement over time for both the MBC protocols and Friendship Bench protocols. Of note, 
there are some themes presented in the fidelity section that speak to participants’ comfort with 
the program and its overall complexity that are pertinent to assessing acceptability. 
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Participant Characteristics 
Of the 936 patients who enrolled in the program after the launch of the intervention, 211 
were depressed at ART initiation (Table 6.1). A total of 14 patients participated in in-depth  








Sex    
   Female 89 6 7 
   Male 122 8 5 
Age** 34.0 (19-65) 36.1(23-47) 34.2 (26-46) 
Health Facility     
   Clinic A 116  14 6 
   Clinic B 174  0 6 
Marital Status    
   Married n/a 6 n/a 
   Single n/a 0 n/a 
   Separated n/a 7 n/a 
Employment    
   Employed n/a 12 n/a 
   Self-employed n/a 0 n/a 
   Unemployed n/a 1 n/a 
Position     
   ART Provider n/a n/a 6 
   Friendship Bench Counselor n/a n/a 4 
   Leadership n/a n/a 2 
Professional Experience    
   Years at clinic  n/a n/a 4.9 (0.7-11) 
   Years as clinician n/a n/a 8.7 (4-15) 
Notes: *Marital status and employment missing (n=1). **Age missing (n=3) and excludes 
leadership. ART=antiretroviral therapy.  
 
interviews. Of these 14 patients, 11 were prescribed antidepressants and three started Friendship 
Bench therapy at ART initiation. As a small number of participants had depression at Clinic B, 
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The clinical data demonstrates that ART providers successfully prescribed 
antidepressants at a therapeutic dose to nearly all (96%) cases of moderate to severe depression, 
achieving high fidelity to the MBC protocol (Table 6.3). Based on the qualitative interviews,  
 





(PHQ-9 score 5-9)* 
Moderate to severe Depression 
(PHQ-9 score ≥10) 
  N=156 N=55 
Counseling by ART provider 15 (10%) 2 (4%) 
Friendship Bench 134 (86%) 0 (0%) 
Antidepressant (AD) 0 (0%) 41 (75%) 
  w/counseling by ART provider 0 (0%) 8 (15%) 
  w/Friendship Bench 2 (1%) 4 (7%) 
None* 5 (3%) 0 (0%) 
   
Of those who start AD N=2 N=53 
 Type     
    Amitriptyline  1 (50%) 37 (70%) 
     Fluoxetine  1 (50%) 16 (30%) 
 Dose     
     Sub-therapeutic dose 0 (0%) 0 (0%) 
     Therapeutic dose   2 (100%) 53 (100%) 
Notes: *Includes 4 patients with missing baseline treatment. ART=antiretroviral therapy. 
PHQ-9=Patient Health Questionnaire-9. 
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ART providers appeared knowledgeable of the depression treatment protocol and how to 
appropriately triage patients based on their PHQ-9 scores. The interviews further suggested that 
providers deviated from guidance to discuss the antidepressant options with patients and jointly 
decide on the best antidepressant. It seemed that providers were most comfortable prescribing 
amitriptyline and that the decision around which antidepressant to prescribe was almost entirely 
governed by what was in stock. As heard from one ART provider: “We just prescribe the 
antidepressants that are in stock at that time, but the first choice is amitriptyline. If amitriptyline 
is not available, then we give that patient the other antidepressant.” While it was not entirely 
clear why ART providers were more comfortable with amitriptyline, leadership and ART 
providers felt that providers were more familiar with amitriptyline and that it was easier for 
patients to take. Patients take amitriptyline daily, while they initially take fluoxetine every other 
day and have to physically cut the pills in half. 
However, the provision of MBC over time was challenging. This may be in part due to 
waning retention over the first 6 months of care. (Figure 6.2). Built using clinical data, Figure 
6.2 shows that by the first follow-up appointment (month 1) only around three quarters of 
participants attended an ART appointment and by month only around a third of participants 
attended an ART appointment. Among those who did come to follow-up HIV care appointments, 
providers often failed to reassess these patients with the PHQ-9, which would have guided 
depression management, or to continue to provide appropriate depression treatment to those who 
were rescreened.  
 The qualitative interviews help explain why it was difficult to identify depressed patients 
returning for care and reassess those patients for depression. ART providers felt both identifying 
patients with depression and reassessing with the PHQ-9 took a lot of time and significantly 
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added to their workload, especially in light of the general shortage of staff and high patient case 
load. For context, study staff timed the administration of the PHQ-9 and ART providers took 
about a minute per question. 
Figure 6.2. Depression treatment engagement, by phase and depressive severity 
 
Notes: *Appropriate treatment is operationalized as attending a Friendship Bench session, or having completed 6 
Friendship Bench sessions for those with mild depression during; or being prescribed antidepressants among those 
with moderate to severe depression. 
 
That said, clinic leadership admitted, “[ART providers] said they get tired and they don’t even 
ask the PHQ because they know that ‘this will take much of my time.’ But if we had more 
personnel more people seeing patients that would have been better.” This statement reveals how 
the added burden of the intervention negatively impacted both attitudes towards the program as 
well as adherence to the program protocol. Identifying patients was also difficult because the 
program was not integrated into the electronic medical records system. Providers had to look for 
stickers on the patients’ health passports that signified they had previously been diagnosed with 











PHQ-9 assessed, but appropriate* treatement NOT provided
PHQ-9 assessed & appropriate* treatment provided
Months Since ART Initiation
Mild Depression (N=156) Moderate to Severe Depression (N=55)
78 
patients’ file, reassess the patient with the PHQ-9, and then provide appropriate treatment. It was 
difficult for providers to determine when a patient no longer needed to be assessed or had 
completed their depression treatment. One ART provider ventured that “there wouldn’t be a 
problem if depression questions were in the electronic system.” As an extension of these issues, 
ART providers often had a poor attitude towards the program. This phenomenon was 
summarized by clinic leadership, “The workload [is problematic] when you are alone in the ART 
room and you need to screen those people with the green sticker, so sometimes people may be 
annoyed, [thinking] ‘I should screen this one, but this will delay me,’” a sentiment echoed by 
other interviewed ART providers. As a result, ART providers often relied on the program 
evaluation staff to identify patients with depression returning for care and the accuracy of the 
follow-up PHQ-9 assessments may have been compromised. 
Few of those with moderate to severe depression received antidepressants continuously 
for the recommended minimum three months based on analysis of the clinical data. (Table 6.4) 
Only six participants received at least three consecutive months of the same antidepressant. 
Switching the type of antidepressant prescribed was common; of the 30 individuals who were 
prescribed antidepressants at least twice, 40% (n=12) changed antidepressants at least once. 
Providers also failed to increase the dose of antidepressants for any of the patients when 
indicated by persistent elevated symptoms.  
The qualitative interviews provided insight into the barriers to achieving the 
recommended duration of antidepressant prescription. The main challenge was rooted in 
identifying patients returning for care, as previously described above. While prescribing 
antidepressants did add to ART providers’ workload, providers were much more concerned 
about the time it took to identify and rescreen patients. When asked specifically about the added 
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workload of prescribing antidepressant, one ART provider responded “now we are supposed to 
check each and every file. If the patient’s file has the sticker [marking a depressed patient’s file] 
it means you have to ask the questions.... the issue is just the time to ask the PHQ only, the time 
to ask the PHQ is what trouble us.”  
 
Table 6.4. Provision of antidepressants to patients with moderate to severe depression at 





Months of AD prescription  
  0 2 (4%) 
  1 23 (42%) 
  2 14 (25%) 
  3 7 (13%) 
  ≥4 9 (16%) 
  
 
Additionally, antidepressant stock-outs were common, as noted by an ART provider: 
“It’s very rare where by you have both [antidepressants] available…, sometimes you find that 
the one [antidepressant the patient started taking] also is not available so we switch them.” 
These reports from the clinics show that switches in antidepressant prescription were not due to 
side effects or to the antidepressants not having the desired effect, but necessitated by stock-outs. 
Ensuring that staff were properly trained on the MBC protocol was also challenging, due to high 
staff turnover and/or rotation through clinic departments and staff availability to attend the 
original trainings or the supervision sessions. Clinic leadership spoke to these needs:   
The training was just a one day one, so most people were not familiar with the dosages so 
they need to be reminded here and there. Of course there are debriefing meetings that are 
done on Thursdays, but still not everybody was attending that review meeting. So 
prescribing is difficult just because people forget the dosage of the medication. 
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This feedback speaks to the complexity of MBC and a need for ongoing support and training. 
From a patient perspective, actually taking antidepressants appeared largely acceptable. While 
some providers were concerned about the added pill burden, patients mostly found the 
antidepressants tolerable; patients did not complain of many side effects nor did they report any 
challenges to antidepressant adherence.  
Friendship Bench 
Clinic staff were only moderately successful at initiating cases of mild depression on 
Friendship Bench therapy. According to the clinical data, while 86% of participants with mild 
depression correctly started the Friendship Bench therapy that same day, the study-employed 
Friendship Bench counselor provided over half of the initial Friendship Bench therapy sessions 
(Table 6.3). As noted by one ART provider, “Most of the times they [Friendship Bench 
counselors] are in the field, so we refer them to the [study-employed counselor],” suggesting 
that the clinic-based Friendship Bench providers were often unavailable and that the clinics often 
relied heavily on the program-employed Friendship Bench counselor.  
The clinical data revealed that few participants with mild depression at ART initiation 
during the intervention phase received consistent Friendship Bench therapy over the course of 
their first six months in care (Table 6.5). The original Friendship Bench therapy protocol was 
designed to be administered over the course of six consecutive weekly sessions. None of the 
patients completed this ideal “full course” in their first two months of care. Only 13 patients 
completed at least six Friendship Bench sessions within their first six months of care. The study-
employed Friendship Bench counselor provided over half of the follow-up Friendship Bench 
therapy sessions. 
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The qualitative interviews help explain the challenges to achieving the recommended 
number of Friendship Bench sessions. Both patients and providers reported that scheduling 
weekly Friendship Bench sessions was almost impossible as the cost of transport was 
prohibitive, alongside expected long wait times at the clinic and the opportunity cost of having to 
take off work. Instead, patients often chose to schedule their Friendship Bench appointments  
 
Table 6.5. Provision of Friendship Bench therapy to patients with mild depression at 
baseline during the intervention phase (N=156) 
 
 Within the first: 




 0 20 (13%) 20 (13%) 
 1 64 (41%) 59 (38%) 
 2 32 (21%) 19 (12%) 
 3 37 (24%) 13 (8%) 
 ≥4 3 (2%) 45 (29%) 
 
monthly in conjunction with their ART appointments. As described by one Friendship Bench 
counselor, “Some [challenges] are transport...we [Friendship Bench counselors] give dates and 
ART give their dates. …So the person weighs the cost…Many are prioritizing coming for [ART] 
medications rather than just coming for the Friendship Bench.” Beyond highlighting the 
complexities of attending follow-up Friendship Bench sessions in light of constrained resources, 
this quote also hints at a disconnect between the ART and depression care for patients on 
Friendship Bench therapy.   
The same staffing challenges that impeded initiating Friendship Bench therapy were also 
raised. The Friendship Bench counselors were not always available due to their competing 
responsibilities as community health workers and the Friendship Bench counselors felt their 
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workload had substantially increased. While the Friendship Bench counselors strove to share the 
added workload, the clinics often relied heavily on the program-employed Friendship Bench 
counselor, previously described. Friendship Bench counselors felt the provision of the Friendship 
Bench therapy was hampered by the sheer number of patients who defaulted or failed to attend 
follow-up sessions. They were frustrated by their inability to adequately trace patients in light of 
phone numbers not working, difficulties locating patients’ residences, and limited funds for 
airtime or transport.  
The qualitative interviews also suggest patient discomfort may have played a role in poor 
continued engagement in Friendship Bench therapy. Interviewed Friendship Bench counselors 
believed it was important to develop rapport with patients and create an environment where 
patients felt comfortable speaking openly and that their privacy would be respected and 
maintained. Patients echoed this sentiment, both as a concern and as something they appreciated 
about the Friendship Bench therapy. As an extension of this, clinic staff and leadership raised 
concerns about the availability of confidential spaces. One Friendship Bench counselor noted 
that other patients were often nearby the Friendship Bench shelters and “when the client sees 
that, they feel that when we tell them that what we are going to discuss is confidential, we cheat 
on them because people are passing by.” This suggests that the open, outdoor nature of these 
shelters may not be conducive to provision of depression counseling in this setting.  
Acceptability 
The qualitative interviews show that nearly all patients, staff and leadership believed both 
MBC and the Friendship Bench helped improve patients’ mental health, relieve their depressive 
symptoms, and prevent risk of suicide. In contrast, the previously published quantitative 
evaluation found that the treatment program did not demonstrably improve retention in HIV care, 
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viral suppression, or depression remission six months after ART initiation.89 In the qualitative 
interviews, ART providers cited patients’ reduced PHQ-9 scores as proof of the effectiveness of 
both antidepressants and the Friendship Bench. The Friendship Bench counselors attributed the 
program’s perceived success to its focus on teaching patients to identify their own problems and 
solutions. Some patients described the specific ways their respective depression treatment helped 
them. For example, patients believed treatment allowed them to calm their thoughts, eat and 
sleep regularly, or, as heard from one patient taking antidepressants, “I am able to talk normally 
and I do not have any anxiety. I am now able to chat with my friends, just like the way life should 
be.” While this patient believed taking antidepressants helped manage their anxiety and 
depression, other patients did demonstrate a lack of understanding of depression, their respective 
depression treatment, and its intended purpose and effect. Patients expressed a reverence for the 
medical field, often stating that they believed their treatment worked simply because the doctors 
told them it would. Finally, both Friendship Bench counselors and ART providers recognized 
that depressed patients may struggle to accept their HIV diagnosis and consistently take their 
ARTs. For example, a Friendship Bench counselor described how “because of the counseling 
session, it helped the people...and now they are taking the medications consistently…this person 
is coming to collect drugs and their outlook [towards their] status has changed,” as did an ART 
provider, “Taking antidepressants have helped our friends with depression … to take their ARVs 
adherently because when they are depressed they don’t even take the ARVs.” These descriptions 
demonstrate that clinic staff perceive that depression treatment supports ART adherence and 
engagement in HIV care. 
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Sustainability  
The clinical data demonstrates the program was not sustained. After enrollment into the 
program evaluation ended, the rate of screening dropped sharply (Table 6.6). By December 
2019, six months after the study staff had complete data abstraction, ART providers had 
completely stopped screening patients newly initiating ART.  





Program Enrollment Period 
(Apr. 2017-Nov. 2018) 
91.8% 90.5% 
Brief Follow-up Period 
(Feb. 2019-May 2019) 
25.1% 58.8% 
Notes: *Among all new ART initiators. **Among those who endorse the 
PHQ-2. PHQ-2=Patient Health Questionnaire-2. PHQ-9=Patient Health 
Questionnaire-9. 
 
These quantitative findings are partially in contrast with staff attitudes towards 
sustainability identified in the qualitative interviews. The staff generally expressed a belief that 
they would continue to screen and manage depression after the study staff left the facilities. As 
heard from one ART provider, “It will continue, because it’s our job us as health workers to 
assist those people, because if we don’t assist, then who will? It’s like most people will not be 
taking the ARVs.” In fact, only two ART providers directly expressed any skepticism towards the 
sustainability of the program, “because there are people who are supporting [us] but if they can 
move out, it is when the true picture of their [providers’] attitude can be seen.” These ART 
providers acknowledged that the clinics receive a lot of support from the study staff and that 
challenges to sustainability may become evident after they leave.  However, clinic staff and 
leadership did suggest certain resources would be key to supporting the sustainability of the 
program. These included increasing the number of trained staff, particularly Friendship Bench 
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providers; refresher trainings and opportunities for continued learning; ongoing supervision; 
maintaining the stock of antidepressants; and space for providing screening and counseling.  
Discussion  
In this mixed-methods process evaluation of a program integrating depression screening 
and treatment into routine HIV care in Malawi, we found relatively poor fidelity in delivering the 
program as intended, variable views towards the program’s acceptability, and a lack of 
sustainability after the conclusion of the program evaluation. After the launch of the intervention, 
HIV providers appeared able to triage patients with depression at ART initiation and start cases 
of moderate to severe depression on the appropriate dose of antidepressants. While most cases of 
mild depression started Friendship Bench therapy at ART initiation, most of those initial 
Friendship Bench sessions were provided by the study-employed counselor as opposed to the 
ART providers. Over time, both ART providers and Friendship Bench counselors struggled to 
provide continued depression treatment. ART providers struggled to identify and reassess 
depressed patients returning for ART, which hampered provision of antidepressants. Staff and 
space availability hindered the provision of Friendship Bench therapy and the cost of transport 
prohibited many patients from attending weekly appointments. The quantitative program 
evaluation did not find that program exposure improved HIV care or depression outcomes.89 
Contrasting with these quantitative findings, patients, clinic staff and leadership generally found 
the depression treatment helpful, suggesting that both antidepressants and the Friendship Bench 
therapy may be acceptable depression treatment options for patients in this setting. The program 
was not sustained after the evaluation concluded, potentially due to limited staff, training, 
infrastructure, and supply of antidepressants. 
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The clinics failed to deliver Friendship Bench therapy with fidelity to the program 
protocol, particularly in regards to the low frequency of attended sessions over the six-month 
duration of follow-up.147 The original Friendship Bench therapy protocol ideally called for six 
weekly therapy sessions, though patients were meant to set their own follow-up appointment 
dates. Similar to our findings, various evaluations of the original Friendship Bench therapy 
program in Zimbabwe suggest low patient engagement may not be uncommon. The pilot 
evaluation found that only 30% of participants completed six sessions in the first six weeks56, the 
randomized control trail found around 40% completed six sessions over a six month period,54 
and a mixed-methods longitudinal study over a five-year period found nearly half of patients 
only attended one session, with only around 6% receiving four or more sessions.148 We found 
that scheduling weekly appointments was challenging for patients, often due to the prohibitive 
cost of transport and spending time at the clinic. Patient follow-up was also difficult for 
providers, in light of limited resources and challenges contacting patients. The mixed-methods 
evaluation of the Friendship Bench in Zimbabwe also noted the lower-than-expected 
appointment attendance and follow-up challenges, which were attributed to the lack of incentives 
for Friendship Bench counselors to follow up with patients.54 While the Friendship Bench is a 
promising approach to providing evidence-based psychosocial therapy, further investigation of 
how best to engage patients over time is needed.  
Providers managed to start the right patients on the correct dose of antidepressants, but 
fidelity to the MBC protocol over time was hampered by stock-outs, ART providers’ level of 
comfort, difficulties identifying depressed patients, lack of integration into the electronic medical 
records system, and negative attitudes. These challenges are unsurprising as the providers are 
already overburdened and were expected to engage with the depression treatment program 
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without additional incentives. A literature review on health systems facilitators and barriers to 
integration of HIV and chronic disease services found that successful integration programs have 
adequate, appropriately skilled, incentivized healthcare workers; supportive institutional 
structures; dedicated resources; strong leadership and political will or support for the program.149 
However, ensuring such a comprehensively supportive environment is particularly challenging in 
resource-limited settings. Furthermore, very few studies have been conducted on task-shifting 
programs that use algorithm-guided protocols for antidepressant prescription in the region, and 
those that have been conducted often do not rely on existing staff or incentivize the staff 
involved in the research.58,59 Further research that seeks to evaluate and compare integrated 
models of care for the provision of antidepressants is urgently needed to ensure the mental health 
needs of people living with HIV are met.71 
Designing implementation science studies to evaluate programs that can readily (and 
rapidly) be adopted and integrated into routine care in the public sector is challenging.76,77 In an 
effort to assess such a depression treatment intervention, our program was intentionally designed 
to rely almost entirely on existing clinical staff and systems. Similarly, the evaluation was 
deliberately designed to influence the provision of care as little as possible. However, it is clear 
that the program-employed Friendship Bench counselors provided a significant proportion of the 
therapy sessions, suggesting this aspect of the program may not have truly been integrated or 
effectively task-shifted to existing community health workers. Further, the study staff likely 
significantly supported both patients and providers involved in the program. The evaluation 
coordinator spent a substantial amount of time supervising and engaging clinic staff and assisting 
in supply-chain management to ensure the availability of antidepressants. The evaluation staff 
may have acted as “expert peers” by helping patients navigate clinical care, likely as a result of 
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engaging patients in the consent process.130 Further, evaluation staff helped providers identify 
depressed patients returning for care, thus artificially inflating the number of patients that would 
have been reassessed or would receive ongoing depression treatment. The lack of sustained 
implementation after the completion of the evaluation further suggests that the dedicated study 
staff on the ground were integral to the program implementation. Implementation science studies 
that are both supporting program implementation and evaluating the program may need to take 
into account how the relationship between the evaluating institution and the study site may affect 
the study itself.  
Several key recommendations have emerged from this experience. As implemented, 
integrating depression treatment into HIV care in resource-limited settings was not feasible and 
the clinics would have benefitted from substantially more support. This mixed-method 
evaluation has identified the following potential facilitators: 
 The presence of a salaried, on-site coordinator or champion employed by the 
Ministry of Health would have increased the likelihood of more faithful 
implementation. Such an individual would have been well-positioned to foster clinic 
ownership of the program and provide the ongoing supervision and training that is 
needed to effectively build and sustain mental healthcare capacity.  
 HTC counselors could administer the entire PHQ-9 at ART initiation. This would 
partially address the added burden of administering the PHQ-9 at ART initiation 
placed on ART providers, who are still well-positioned to interpret the results and 
provide appropriate treatment.  
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 Integration into the electronic medical records system is critical. This integration 
would help ensure that screening was completed and that returning patients were re-
assessed.  
 Finally, successful implementation requires a dedicated, clinic-based Friendship 
Bench counselor. Task-shifting to an already overburdened cadre of community 
health workers was an ineffective means of providing depression services. 
Limitations  
Findings from this mixed-method process evaluation should be considered in light of 
limitations due to the program and evaluation design. First, neither the program nor the 
evaluation design were guided by a formal implementation science framework. However, both 
were designed in congruence with the key principles of implementation science, using methods 
that would promote the systematic uptake of evidence-based practices (e.g. the Friendship Bench 
and algorithm-based care) into routine care.142,143 Further, we have drawn from various 
implementation science frameworks for this process evaluation to help ground this mixed-
methods approach in implementation science theory.145,147 A convenience sample of health care 
facility staff and patients from the program sites participated in the interviews. Notably, patients 
invited to participate in the interviews had to still be engaging with HIV care, and may have had 
very different opinions about the depression treatment program than those who did not continue 
to seek care at the program sites. Thus, the attitudes captured here may not be generalizable to all 
of the patients exposed to the screening and treatment program. Further, as the main objective of 
the study was to evaluate a program at the sites where participants worked or received care, it is 
possible that participants’ responses were subject to social desirability bias. As evident from one 
participant being asked to explain how they believe antidepressants had helped them: “I do not 
90 
know whether my response to this question is right. I do not know, I am just repeating over and 
over again. You should correct me sometimes.” However, the use of mixed-methods approaches 
is particularly useful for evaluating implementation outcomes.145 In this process evaluation, the 
experiences and opinions captured in the qualitative interviews help contextualize and provide 
nuanced information about the reasons behind the program’s shortcomings.  
Conclusion 
This depression treatment program was not delivered as intended, as fidelity to the 
program protocol was poor. While antidepressants and problem-solving therapy appeared to be 
acceptable treatment options for patients, clinic staff and leadership found delivering this 
treatment challenging in light of constrained human resources and infrastructure. These 
challenges may be responsible for the program’s lack of impact on retention, viral suppression, 
and depression remission.89 The program was not ultimately sustained after the conclusion of the 
formal evaluation. Without substantial support to supervise the implementation of the program, 
continue to build and maintain the capacity of providers, integrate the program in the electronic 
medical records system, and ensure the availability of Friendship Bench counselors, integrating 
such a depression treatment program into HIV care in this setting may not be feasible. This 
process evaluation helps explain why this implementation strategy did not work and provides 
valuable insight into how it could be improved. Taking these findings forward, further research is 
needed to test enhanced implementation strategies for integrating evidence-based mental health 






CHAPTER VII: CONCLUSIONS 
 
Summary of Findings 
 In light of research suggesting that depression undermines engagement in HIV care and 
that treating depression can improve depression and HIV outcomes, the Malawi Ministry of 
Health (MOH) integrated depression management into HIV care at two clinics in Lilongwe, 
Malawi. This pilot task-shifting program, called SOAR-Mental Health (SOAR-MH), moved 
psychiatric screening and management responsibilities to non-specialists. The program was 
implemented in two phases, a screening-only control phase and an intervention treatment phase. 
During the control phase, adult patients newly initiating antiretroviral therapy (ART) were 
screened for depression, but those with depression were managed following the existing standard 
of care which primarily consisted of brief supportive counseling by the HIV medical provider 
and thus did not receive evidence-based depression treatment. During the intervention phase, 
Friendship Bench problem-solving therapy or algorithm-guided antidepressant treatment was 
offered to patients with elevated depressive symptoms based on their depressive severity.  
Aim 1 of this dissertation investigated whether HIV care engagement differed for those 
with and without depression in the absence of evidence-based depression treatment. This first 
aim only included participants who initiated care during the screening-only phase of SOAR-MH 
and compared retention in HIV care and viral suppression at six months between those with and 
without depression at baseline. The prevalence of depression among this population was 27%. 
We ultimately found that HIV care outcomes did not vary between those with and without 
depression at baseline.   
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Aim 2 of this dissertation evaluated the impact of the depression treatment program on 
HIV care and depression outcomes at six months. This second aim only included participants 
with depression at ART initiation and compared retention in HIV care, viral suppression, and 
depression remission between those who initiated during the screening-only control phase (who 
were unexposed to the program) and those who initiated during the intervention phase (who were 
exposed to the program). While almost all of the patients who initiated during the intervention 
phase started the appropriate depression treatment, we ultimately found that few participants in 
the intervention group received consistent depression treatment over their first six months in 
care. Further, program exposure did not demonstrably affect most HIV or mental health 
outcomes, though the probability of currently being on ART at six months was significantly 
lower among the intervention group than the control group [RR 0.6(95%CI: 0.4-0.9)]. 
Aim 3 of this dissertation examined the implementation of the SOAR-MH treatment 
program by focusing on implementation fidelity, acceptability, and sustainability. Using a 
mixed-methods approach, we used clinical data to describe the implementation of the program 
and qualitative interviews with clinic staff and patients to contextualize and explain these 
findings. There were many challenges to implementing this task-shifting depression program as 
intended. Using existing HIV testing and counseling (HTC) workers and ART providers to 
identify patients with depression at ART initiation appeared feasible. However, fidelity to the 
program protocol was poor. While antidepressants and problem-solving therapy appeared to be 
acceptable treatment options for patients, clinic staff and leadership found delivering these 
treatment options challenging in light of constrained human resources and infrastructure. The 
program was not sustained.  
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Strengths and Limitations 
The results presented in this dissertation should be considered in light of several 
limitations.  Due to the implementation science nature of this study, the covariates captured were 
limited to routinely collected clinical data. In order to design a study that would promote the 
systematic uptake of evidence-based practices into routine care, the study team strove to limit the 
evaluation’s influence on the provision of or engagement in care. As such, all of the measures 
were drawn from routinely collected medical chart data. We did not conduct baseline interviews 
or schedule six-month follow-up interviews, and we captured limited information on potential 
confounders. While the multiple baseline design used in the Aim 2 analysis should have 
protected against confounding from unmeasured confounders by producing balanced 
characteristics across phases, it is possible that the presented analyses were biased by 
unmeasured confounding factors. 
A large proportion of patients did not have data on six-month viral loads or PHQ-9 
scores, due to either dropout or provider failure to refer patients for viral load testing or to screen 
patients appropriately. As such, it is possible that we overestimated depression remission and 
viral suppression as six-month PHQ-9s and viral loads could only be established for patients who 
remained in care. Further exacerbating these issues, it is possible that part of the observed 
reduction in PHQ-9 scores could be due to less careful administration of the PHQ-9 at six 
months. Additionally, a large proportion of patients who did return for care at six months were 
never sent for viral load testing.  
All of the HIV engagement measures may have been influenced by participants who 
sought care at another facility without formally transferring their records. These “silent transfers” 
would have been misclassified as being out of care. However, as the rate of silent transfers 
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should not have varied between groups, this potential measurement error should not have 
introduced substantial bias into either of the Aim 1 or Aim 2 analyses. 
It is also possible that providers inaccurately identified cases of depression using the 
PHQ-9. The PHQ-9 is not a diagnostic tool, but a questionnaire that assesses the presence of the 
nine core symptoms of depression and has yet to be validated among people living with HIV in 
Malawi. However, the PHQ-9 was specifically chosen for use in this program because it has 
been widely used and validated among people living with HIV in SSA81-83, works well both as a 
case identification tool as well as a longitudinal monitor of response to treatment, and has been 
validated among a Malawian population of people living with diabetes.120 Again, it is possible 
that the ART providers incorrectly administered the PHQ-9 to patients. However, capacity-
building meetings and check-ins were held throughout the program implementation to support 
providers and to help ensure they understood how to use and interpret the tool. Furthermore, we 
did a small sub-study comparing the providers’ administration of the PHQ-9 to that of trained 
research assistants. While we found that research assistants identified more cases of depression 
than providers, there was still high overall agreement between providers and research 
assistants.122  
 There are also some limitations unique to the qualitative analysis presented in Aim 3. A 
convenience sample of health care facility staff and patients from the program sites participated 
in the interviews. Notably, patients invited to participate in the interviews had to still be 
engaging with HIV care, and may have had very different opinions about the depression 
treatment program than those who did not continue to seek care at the program sites. Thus, the 
attitudes captured here may not be generalizable to all of the patients exposed to the screening 
and treatment program. Further, as the main objective of the study was to evaluate a program at 
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the sites where participants worked or received care, it is possible that participants’ responses 
were subject to social desirability bias. Nonetheless, the experiences and opinions captured in the 
interviews help contextualize and provide useful insights explaining some of the program’s value 
and shortcomings.  
Interpretation and Implications of Findings 
 The Malawi MOH integrated a depression treatment program offering Friendship Bench 
problem-solving therapy and algorithm-guided antidepressant treatment into ART initiation at 
two clinics in Lilongwe, Malawi. The impetus for implementing this program was that research 
has documented a high prevalence of depression among people living with HIV in Malawi and 
has found that depression can undermine engagement in HIV care.1-6 While studies have shown 
the efficacy of various evidence-based treatment protocols for using Friendship Bench therapy 
and antidepressants to manage depression symptoms in low-income settings, the best methods 
for providing psychiatric services in such settings are not often clear.56,58-61 As such, the 
evaluation of this program was designed to test whether this implementation method was an 
effective means of providing depression services for people initiating ART and improving HIV 
care and depression outcomes.  
In parallel with understanding and evaluating the implementation of this program, this 
dissertation accomplished three goals. First, it investigated the questions guiding the premise or 
motivation for implementing this program. Namely, is there a high prevalence of depression 
among people newly initiating ART and is depression at ART initiation associated with reduced 
retention in HIV care? Second, it evaluated the implementation of the program and its impact on 
HIV care and depression outcomes. Third, it examined the implementation of the program in an 
effort to explain the program’s failure to improve patient outcomes.  
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The prevalence of depression among patients newly starting ART was quite high – 
around a quarter of those enrolled who completed the PHQ-9 screening reported mild to severe 
depressive symptoms. This finding is in line with previous research conducted in Malawi which 
found a prevalence of depression ranging between 1% and 19% among various subpopulations 
(adolescents, pregnant women, adults receiving HIV care) of people living with HIV 35,37,107,112, 
and supports other sub-Saharan regional estimates of depression prevalence.1 Such evidence 
confirms a high burden of depression among people living with HIV and does indicate a clear 
need for depression treatment among people living with HIV. 
However, depression at ART initiation was not associated with any of the retention 
metrics for HIV care engagement and viral suppression at six months. Key to interpreting this 
finding is recognizing that these retention metrics were all dictated by appointment attendance. 
While the association between depression and reduced ART adherence is relatively well-
established2,115, the effect of depression on overall engagement in HIV care is less understood 
and few studies have investigated this specific aspect of the depression-HIV care engagement 
relationship. Several studies conducted in the region examining the association between 
depression prior to HIV testing and linkage to care had mixed results, as previously 
described.44,116,117  Research into the effect of depression on HIV care engagement suggests that 
depression manifests through loss of interest, poor concentration, poor motivation, reduced self-
efficacy, fatigue, hopelessness, and suicidality.2,4,46 While these mechanisms may directly impact 
daily ART adherence, they may have less of an effect on monthly clinic attendance. As such, it is 
not evident that untreated depression is driving reduced retention among people newly initiating 
ART in this setting. 
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The program evaluation found that while nearly all patients were correctly screened for 
depression and, following the launch of the treatment phase, depressed patients initiated the 
appropriate treatment, the continued provision of depression treatment was nonetheless 
challenging. Both clinical and qualitative data were used to describe and explain the following 
key aspects of the program implementation across both phases in the Aim 2 and Aim 3 analyses: 
depression screening, depression treatment initiation, and depression treatment engagement over 
time.  
Integrating depression screening and depression treatment initiation into HIV care 
appeared feasible at the clinic sites. Nearly all patients who initiated ART during the program 
evaluation were completely screened for depression. ART providers also managed to 
appropriately triage cases of depression and start patients on the appropriate depression treatment 
during the intervention phase. Another task-shifting study in Uganda found that both depression 
screening by lay workers and antidepressant treatment initiation by ART providers were feasible, 
a success the researchers attributed to ongoing training and appropriate mentorship.60 Factors 
that may have contributed to this success in our study include efforts to ensure that every HIV 
provider received training in how to administer and interpret the PHQ-9; the effective utilization 
of existing ART initiation processes; and the creation of a collaborative training environment.130 
However, as a caveat to this success, it is evident from the interviews with clinic staff that the 
research assistants may have played a role in escorting patients from HTC to ART initiation and 
ensuring that the ART providers actually completed the PHQ-9 when necessary patients. 
Furthermore, the program-employed Friendship Bench counselor provided over half of the initial 
Friendship Bench therapy sessions, often because the existing clinic-based Friendship Bench 
counselors were unavailable. Nevertheless, these findings suggest that using public-sector, non-
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psychiatric specialists to screen patients newly initiating ART for depression and initiate 
depressed patients on appropriate treatment is possible in this low-resource SSA setting.  
The clinic staff struggled to provide continuous depression treatment over time in light of 
human resource constraints, an inability to effectively integrate depression management into 
existing clinic infrastructure, and supply chain management inadequacies. Very few patients 
received ongoing depression treatment. The difficulties of providing ongoing depression 
treatment seemed to largely stem from challenges in re-identifying depressed patients returning 
for care, persistent stock-outs of antidepressants, the lack of availability of Friendship Bench 
therapy counselors, and the inability of patients to return for Friendship Bench therapy sessions. 
ART providers struggled to re-identify patients returning for care for several reasons. 
First, these providers often relied on the electronic medical record (EMR) to provide ART, but 
the EMR did not include a depression screening module. Despite efforts to mark patients’ 
physical files, this often resulted in patients not being reassessed with the PHQ-9 at their follow-
up visits or substantial reliance on the research assistants to help providers identify patients and 
ensure they were rescreened. Second, the interviews with providers revealed that some providers 
felt overburdened and were frustrated with the time it took to identify patients and administer the 
entire PHQ-9, suggesting some unwillingness to implement the program.  
As an extension of this challenge, when patients on antidepressants were not re-identified 
at follow-up visits, providers were then unable to assess these patients’ response to the 
antidepressants or further prescribe depression medication. Exacerbating this challenge, 
medication stock-outs were common. While amitriptyline and fluoxetine are both considered 
essential medicines in Malawi and are meant to be stocked at public-sector pharmacies, ensuring 
their availability proved complicated and required substantial coordination. Other countries in 
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the region with similar essential medicine policies have also experienced challenges stocking 
these medications at the district or clinic level.136 Similarly, another task-shifting depression 
program in Tanzania also experienced anti-depressant stock-outs.58 Ensuring the stock of 
antidepressants is maintained would have required greater engagement and investment of health 
sector stakeholders involved in the procurement, supply, and distribution of psychiatric 
medications.  
The provision of and engagement with the Friendship Bench therapy over time was also 
challenging. The original Friendship Bench therapy protocol ideally called for six weekly 
therapy sessions, though patients were meant to set their own follow-up appointment dates in 
congruence with the Friendship Bench patient-centered approach. In our setting, almost none of 
the participants chose to attend weekly sessions and very few participants managed to receive six 
sessions within their first six months in care. Interviews with patients and providers revealed that 
patients found the cost of transport prohibitive, alongside expected long wait times at the clinic 
and the high opportunity cost of having to take off work. Additionally, the clinic-employed 
Friendship Bench therapy counselors were often unavailable due to their competing 
responsibilities as community health workers. As a result, the program-employed Friendship 
Bench counselor provided many of the Friendship Bench therapy sessions. A mixed-methods 
evaluation of the Friendship Bench in Zimbabwe also noted the lower-than-expected 
appointment attendance and follow-up challenges, but that evaluation did not identify patient-
driven barriers to appointment attendance.54 While the Friendship Bench is a promising approach 
to providing evidence-based psychosocial therapy, further investigation of how best to engage 
patients over time is needed as the model is adapted for implementation in varying settings.  
100 
The lack of other studies on task-shifting models of care in the region – in particular, 
studies which have relied on existing staff (as opposed to study-employed staff) or assessed the 
provision of depression treatment over time – make drawing comparisons to this study 
particularly challenging. This gap in available research demonstrates a clear need to investigate 
the provision of and engagement in depression treatment over time in real-world, low-resource 
settings. 
The program evaluation ultimately found that exposure to the program as implemented 
was not associated with improved HIV care or depression outcomes. These findings persisted 
even when using the “treatment started” or “as treated” approach, and in the main analysis the 
intervention group was significantly less likely to currently be on ART at six months than the 
control group. Other studies conducted in the region have found that similar programs can 
effectively treat depression, though these programs often had higher fidelity to their treatment 
protocols over time.74,131  However, research linking depression treatment to improvements 
across the HIV care cascade is mixed.7-15,53,139,140  Nevertheless, the interviews with clinic 
leadership, providers, and patients all indicate that depression treatment could be valuable and 
important for patients with elevated depressive symptoms. While the evaluation did not yield 
evidence that the program improved HIV care or depression outcomes in a real-world clinic 
setting, depression treatment in sub-Saharan Africa is efficacious for improving mental health 
and engagement in HIV care in more controlled research environments.74 As such, one could 
conclude this implementation strategy failed to deliver effective treatment and that further 
support and investment would be needed to ensure depressed patients receive sustained 
evidence-based treatment.  
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Other explanations for the main findings in the Aim 1 and Aim 2 analyses may lie in the 
study design itself. As it would have been unethical to entirely withhold depression treatment 
from patients during the screening-only control phase, ART providers were at liberty to address 
patients’ depression ad hoc. The qualitative interviews used in Aim 3 analysis suggest that 
individuals identified with depression during the control phase possibly received additional 
supportive counseling on accepting their HIV status, ART adherence, and managing their 
depression. While this supportive counseling is not evidence-based depression treatment, patients 
still could have benefited from this additional attention. In fact, a recent meta-analysis of 
depression treatment interventions for people living with HIV in sub-Saharan Africa concluded 
that the programs with an ART adherence component had the greatest impact on HIV 
outcomes.131 As a result, depressed patients may have been more likely to remain engaged in 
care through six months compared to their non-depressed counterparts during the control phase 
(Aim 1) as well as compared to their depressed counterparts who were exposed to evidence-
based treatment during the intervention phase (Aim 2).  
While depression at ART initiation was not associated with retention in HIV care at six 
months and depression treatment did not improve, it is worth noting that retention among the 
study population was astoundingly low. It is possible that we potentially underestimated 
retention in care due to “silent transfers,” or individuals who decided to access care at a different 
location without formally transferring their records. In fact, the Malawi MOH assumes that 
actual retention is likely 10% higher due to this misclassification of “silent transfers” as 
“defaulters” in clinic-based retention analysis, as ART registries are not yet nationally linked.90 
However, a meta-analysis of low- and middle-income country studies suggests retention may be 
as much as 18% higher.124 Still, it is likely that this population faced other barriers to care that 
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were more relevant and difficult to overcome, such as human resource and institutional 
challenges, distance to the clinic, lack of support, and stigma and fear of HIV status 
disclosure.24,29-31 There is a distinct need for urgent action to improve both mental health and 
early retention in care for people living with HIV and depression and to develop innovative 
methods for measuring the complexities of retention in care in low-resource settings.  
Future Directions 
Findings from this dissertation suggest a need for future research is several key areas. 
Further investigation is warranted into: 1) the key factors impeding sustained engagement in HIV 
care in Malawi; 2) the mechanisms through which depression treatment undermines engagement 
in HIV care; and 3) how to best provide psychiatric services to people living with HIV and the 
general public in Malawi and other low-resource settings. 
Retention in HIV care at six months among the study population was quite low. Attrition 
across the HIV care cascade will worsen patient health outcomes, hamper epidemic control, and 
present a major obstacle to achieving the UNAIDS 90-90-90 goals.26-28 While depression at ART 
initiation was not associated with retention in HIV care at six months and depression treatment 
similarly did not improve retention in HIV care, research has shown that other factors such as 
human resource and institutional challenges, distance to the clinic, lack of support, stigma and 
fear of HIV status disclosure, as well as psychiatric illness may constitute barriers to HIV care 
engagement.24,29-31 In order to improve retention in HIV care, future research will need to unpack 
and understand the factors that constitute the most salient barriers to HIV care engagement.  
The impact of depression on engagement in HIV care is complicated. Research has 
shown that depression may manifest through loss of interest, poor concentration, poor 
motivation, reduced self-efficacy, fatigue, hopelessness, and suicidality.2,4,46 These factors could 
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all plausibly undermine patients’ ability to take daily medication and attend monthly 
appointments, the two key aspects of successful retention in HIV care.  However, while we 
hypothesized that untreated depression would undermine retention in HIV care and that treating 
depression would lead to improved retention in HIV care, we ultimately found neither of these 
associations among our study population. As research on the associations between depression, 
depression treatment, and various HIV care outcomes remains mixed2,7-15,44,53,115-117,139,140, further 
efforts to understand the relationship between depression and HIV will need to specifically 
unpack the mechanisms through which depression impacts the different aspects of HIV care 
engagement.  
Designing implementation science studies to evaluate programs that can readily (and 
rapidly) be adopted and integrated into routine care in the public sector is challenging.76,77 
Despite our best efforts, it was difficult to prevent the program evaluation from influencing the 
provision of depression treatment at the clinics. As a result, the clinic staff relied heavily on the 
research assistants. Furthermore, we are limited in our ability to truly know what the program 
would have looked like in the absence of outside support. The program evaluation identified 
many challenges to integrating depression treatment into HIV care at the study sites and found 
that the program, as implemented, did not improve HIV care or depression outcomes. As such, 
other depression implementation strategies will need to be identified in order to address the high 
burden of depression among this vulnerable population. Further implementation science research 
is needed to understand how best to integrate mental health care into existing healthcare systems 
for people living with HIV and the general public in Malawi and other low-resource settings. 
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Conclusions 
This dissertation evaluated a program that integrated depression screening and treatment 
into ART initiation at two clinics in Malawi. In the absence of evidence-based depression 
treatment, depression at ART initiation was not associated with any of the HIV care retention 
metrics at six months. Among those with depression at ART initiation, exposure to the treatment 
program was also not associated with improved depression remission or any of the HIV care 
retention metrics. There were many challenges to implementing this depression treatment 
program. The provision of continuous depression treatment over time was particularly difficult. 
As implemented, this depression treatment program ultimately did not appear feasible or 
sustainable without additional support.  Future research is needed to better understand the 
mechanisms through which depression and depression treatment affect the various aspects of 
HIV care engagement and to develop improved means of providing mental health services in 








Appendix Table 1. Program impact on HIV and depression outcomes, among those with 
mild depressive symptoms (N=370) 
 




 Retention: never >14 days through 6 months 68/199 (34%) 49/136 (36%) 
 HIV appointment attendance: average proportion of   
 scheduled appointments attended through 6 months  
 (Range: 0-1) 0.6 (0.4) 0.6 (0.4) 
   Currently on ART: attended appointment prior to 6 months 
   with next scheduled appointment after 6 months 106/199 (53%) 66/136 (49%) 
   Consistent ART:  never >5 days without ART through  
   6 months 85/199 (43%) 55/136 (40%) 
   ART pill possession: average proportion of days with ART 
   through 6 months (Range: 0.16-1) 0.7 (0.4) 0.7 (0.4) 
   Viral suppression: VL < 1,000 copies/mL after 5.5 months,  
   among those with a viral load 83/88 (94%) 45/49 (92%) 
   Depression remission: PHQ-9 score < 5 after 5.5 months,  
   among those with a PHQ-9 score 63/67 (94%) 27/28 (96%) 
Notes: This table does not include data on individuals who transferred within the first 6 months of care: Control 
Phase n=15; Intervention Phase n=20. Denominators vary due to viral loads not being drawn, the PHQ-9 not being 
administered, and not having or attending a scheduled appointment around 6 months. ART=antiretroviral therapy. 




Appendix Table 2. Program impact on HIV and depression outcomes, among those with 
moderate to severe depressive symptoms (N=131) 
 





  Retention: never >14 days through 6 months 23/67 (34%) 17/50 (34%) 
 HIV appointment attendance: average proportion of  
 scheduled appointments attended through 6 months  
 (Range: 0-1) 0.5 (0.4) 0.6 (0.4) 
   Currently on ART: attended appointment prior to 6 months  
   with next scheduled appointment after 6 months 32/67 (48%) 21/50 (42%) 
   Consistent ART:  never >5 days without ART through  
   6 months 27/67 (40%) 18/50 (36%) 
   ART pill possession: average proportion of days with ART  
   through 6 months (Range: 0.16-1) 0.7 (0.4) 0.7 (0.4) 
   Viral suppression: VL < 1,000 copies/mL after 5.5 months,  
   among those with a viral load 25/27 (93%) 15/17 (88%) 
   Depression remission: PHQ-9 score < 5 after 5.5 months,  
   among those with a PHQ-9 score 24/26 (92%) 10/10 (100%) 
Notes: This table does not include data on individuals who transferred within the first 6 months of care: Control 
Phase n=9; Intervention Phase n=5. Denominators vary due to viral loads not being drawn, the PHQ-9 not being 
administered, and not having or attending a scheduled appointment around 6 months. ART=antiretroviral therapy. 




Appendix Table 3. Program impact on HIV and depression outcomes, “treatment started” 
approach* (N=502) 
 
 n(%) or mean(sd) Untreated Started 
Treatment 
 Retention: never >14 days through 6 months 88/269 (33%) 69/183 (38%) 
 HIV appointment attendance: average proportion of  
 scheduled appointments attended through 6 months  
 (Range: 0-1) 0.6 (0) 0.6 (0) 
   Currently on ART: attended appointment prior to 6 months  
   with next scheduled appointment after 6 months 135/269 (50%) 90/183 (49%) 
   Consistent ART:  never >5 days without ART through  
   6 months 108/269 (40%) 77/183 (42%) 
   ART pill possession: average proportion of days with ART 
   through 6 months (Range: 0.16-1) 0.7 (0.4) 0.7 (0.4) 
   Viral suppression: VL < 1,000 copies/mL after 5.5 months, 
   among those with a viral load 103/109 (94%) 65/72 (90%) 
   Depression remission: PHQ-9 score < 5 after 5.5 months,  
   among those with a PHQ-9 score 82/87 (94%) 42/44 (95%) 
Notes: *“Treatment started” approach compares patients who started the Friendship Bench or antidepressants to 
patients who did not start either. This table does not include data on individuals who transferred within the first 6 
months of care: Untreated n=27; Started Treatment n=22. Denominators vary due to viral loads not being drawn, the 
PHQ-9 not being administered, and not having or attending a scheduled appointment around 6 months. 





Appendix Table 4. Program impact on HIV and depression outcomes, “As treated” 
approach* (N=355) 
 
n (%) or mean (sd) Inadequate Adequate 
 Retention: never >14 days through 6 months 125/268 (47%) 32/54 (59%) 
 HIV appointment attendance: average proportion of  
 scheduled appointments attended through 6 months  
 (Range: 0-1) 0.8 (0) 0.8 (0) 
   Currently on ART: attended appointment prior to 6 months 
   with next scheduled appointment after 6 months 168/268 (62%) 38/54 (70%) 
   Consistent ART:  never >5 days without ART through  
   6 months 137/268 (51%) 32/54 (59%) 
   ART pill possession: average proportion of days with ART 
   through 6 months (Range: 0.16-1) 0.8 (0.3) 0.9 (0.2) 
   Viral suppression: VL < 1,000 copies/mL after 5.5 months, 
   among those with a viral load 126/134 (95%) 25/29 (86%) 
   Depression remission: PHQ-9 score < 5 after 5.5 months,  
   among those with a PHQ-9 score 96/103 (93%) 22/22 (100%) 
Notes: *“As treated” approach compares patients who received at least two Friendship Bench therapy sessions or 
their first two months antidepressants to patients who did not, restricted to those who attended at least their first 
follow-up visit. This table does not include data on individuals who transferred within the first 6 months of care: 
Inadequate n=25; Adequate n=9. Denominators vary due to viral loads not being drawn, the PHQ-9 not being 
administered, not having or attending a scheduled appointment around 6 months. ART=antiretroviral therapy. PHQ-






Appendix Table 5. Participant characteristics, by transfer (N=501)  
 
n (%) or mean (sd) Overall Did Not 
Transfer 
Transferred 
Overall 501 452 49 
Clinic 
   
   Clinic A 276 (55%) 239 (53%) 37 (76%) 
   Clinic B 225 (45%) 213 (47%) 12 (24%) 
Sex 
   
   Male 214 (43%) 193 (43%) 21 (43%) 
   Female 287 (57%) 259 (57%) 28 (57%) 
Age 33.8 (9.5) 33.9 (9.5) 33.2 (8.9) 
Baseline Depression Severity 
   
   Mild (PHQ-9: 5-9)  370 (74%) 335 (74%) 35 (71%) 
   Moderate to severe (PHQ-9: 10-27)  131 (26%) 117 (26%) 14 (29%) 
Baseline Suicidality 
   
   No thoughts 397 (79%) 354 (78%) 43 (88%) 
   Suicidal thoughts 104 (21%) 98 (22%) 6 (12%) 




Appendix Table 6. Participant characteristics, by viral load data (N=255)  
 
n (%) or mean (sd) Overall Viral Load Data Attended, but 
no Viral Load 
Data  
Overall 255 181 74 
Clinic 
   
   Clinic A 148 (59%) 109 (60%) 39 (53%) 
   Clinic B 107 (41%) 72 (40%) 35 (47%) 
Sex 
   
   Male 110 (43%) 70 (39%) 40 (54%) 
   Female 145 (57%) 111 (61%) 34 (46%) 
Age 33.8 (9.5) 35.3 (9.8) 34.9 (9.2) 
Baseline Depression Severity 
   
   Mild (PHQ-9: 5-9)  189 (74%) 137 (76%) 52 (70%) 
   Moderate to severe (PHQ-9: 10-27)  66 (26%) 44 (24%) 22 (30%) 
Baseline Suicidality 
   
   No thoughts 195 (76%) 133 (73%) 62 (84%) 
   Suicidal thoughts 60 (24%) 48 (27%) 12 (16%) 




Appendix Table 7. Participant characteristics, by 6-month PHQ-9 data (N=241)  
n (%) or mean (sd) Overall PHQ-9 Attended, but 
no PHQ-9  
Overall 241 131 110 
Clinic 
   
   Clinic A 143 (59%) 80 (61%) 63 (57%) 
   Clinic B 98 (41%) 51 (39%) 47 (42%) 
Sex 
   
   Male 104 (43%) 53 (40%) 51 (46%) 
   Female 137 (57%) 78 (60%) 589(54%) 
Age 33.8 (9.5) 35.2 (10.2) 35.2 (8.9) 
Baseline Depression Severity 
   
   Mild (PHQ-9: 5-9)  178 (74%) 95 (73%) 83 (75%) 
   Moderate to severe (PHQ-9: 10-27)  63 (26%) 36 (27%) 27 (25%) 
Baseline Suicidality 
   
   No thoughts 185 (77%) 96 (73%) 89 (81%) 
   Suicidal thoughts 56 (23%) 35 (27%) 21 (19%) 




Appendix Table 8. Association between depression treatment and HIV care and depression 
outcomes, by depressive severity at baseline 
 
  Mild Moderate to Severe 
 aRR or Mean Difference (95%CI) 
  Retention: never >14 days through 6 months 1.2 (0.6-2.3) 0.8 (0.3-2.4) 
    HIV appointment attendance: average proportion of 
    scheduled appointments attended through 6 months 
0.0 (-0.1-0.2) -0.1 (-0.4-0.2) 
   Currently on ART: attended appointment prior to 6  
   months with next scheduled appointment after  
   6 months 
0.7 (0.5-1.1) 0.3 (0.1-0.8) 
   Consistent ART:  never >5 days without ART through  
   6 months 
0.8 (0.5-1.4)  
   ART pill possession: average proportion of days with  
   ART through 6 months 
-0.1 (-0.3-0.0) -0.2 (-0.5-0.1) 




Appendix Table 9. Association between depression treatment and HIV care and depression 
outcomes, “treatment started” approach* 
 
 Outcome Adjusted** Imputation*** 
 RR or Mean Difference (95%CI) 
  Retention: never >14 days through 6 months 1.4 (0.9-2.1) 1.4 (0.9-2.1) 
    HIV appointment attendance: average proportion of 
    scheduled appointments attended through 6 months 
0.1 (0.0-0.2) 0.0 (-0.1-0.1) 
   Currently on ART: attended appointment prior to 6 months 
   with next scheduled appointment after 6 months 
1.0 (0.8-1.3) 1.0 (0.8-1.3) 
   Consistent ART:  never >5 days without ART through  
   6 months 
1.2 (0.8-1.7) 1.2 (0.8-1.7) 
   ART pill possession: average proportion of days with ART 
   through 6 months 
0.1 (-0.1-0.1) 0.0 (-0.1-0.1) 
Notes: *“Treatment started” approach compares patients who started the Friendship Bench or antidepressants to 
patients who did not start either. **Adjusted for clinic, months since program launch (quadratic term), sex, and 




Appendix Table 10. Association between depression treatment and HIV care and 
depression outcomes, “as treated” approach* 
 
 Outcome Adjusted** Imputation*** 
 RR or Mean Difference (95%CI) 
 Retention: never >14 days through 6 months 1.3 (1.0-1.9) 1.4 (1.0-2.0) 
   HIV appointment attendance: average proportion of 
   scheduled appointments attended through 6 months 
0.1 (0.0-0.1) 0.3 (0.2-0.4) 
   Currently on ART: attended appointment prior to 6 months 
   with next scheduled appointment after 6 months 
1.1 (0.9-1.4) 1.2 (0.9-1.5) 
   Consistent ART:  never >5 days without ART through  
   6 months 
1.1 (0.8-1.5) 1.1 (0.8-1.6) 
   ART pill possession: average proportion of days with ART 
   through 6 months 
0.1 (0.0-0.2) 0.1 (0.0-0.1) 
Notes: *“As treated” approach compares patients who received at least two Friendship Bench therapy sessions or 
their first two months antidepressants to patients who did not, restricted to only those who attended at least their first 
follow-up visit. **Adjusted for clinic, months since program launch (quadratic term), sex, and baseline depressive 
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